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 Several structured and quantitative approaches have been developed to determine 
the benefit-harm balance of medical treatments in specific populations. These approaches 
summarize the key factors of a benefit-harm assessment that may include baseline 
outcome risks, treatment effects and relative importance for outcomes. The overarching 
goal of this dissertation was to develop a patient-centered approach to benefit-harm 
assessment in treatment decision-making.  
 In part one of this dissertation, we reviewed the labels and medical reviews of 58 
drugs approved by the US Food and Drug Administration for four diseases to learn how 
they dealt with surrogate outcomes when they were assessing the benefits and harms of 
drugs. Most drugs for chronic obstructive pulmonary disease, diabetes, and glaucoma 
were approved based only on surrogates but for osteoporosis, most drugs were also 
approved for patient-centered outcomes. The rationale for using surrogates was not often 
discussed (11 out of the 43 drug approvals based only on surrogates, 26%) in medical 
reviews. We accordingly proposed a framework for use of surrogate outcomes in doing  
patient-centered benefit-harm assessments. 
  In part two of this dissertation, we conducted a survey of patients with non-
infectious uveitis to elicit their preferences for six treatment outcomes associated with 
corticosteroid therapy. Eighty-two patients in the Multicenter Uveitis Steroid Treatment 
(MUST) Trial Follow-up Study and 100 patients treated at two academic medical centers 
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(Johns Hopkins University and University of Pennsylvania) completed the best-worst 
scaling tasks, in which they repeatedly selected the most and least worrying from a list of 
three outcomes. Results showed that participants were more likely to select vision not 
meeting the requirement for driving, glaucoma, and needing eye surgery as the most 
worrying outcomes as compared against needing medicine for high blood 
pressure/cholesterol, cataracts or infection (e.g., sinusitis). 
 In part three of this dissertation, we conducted a quantitative benefit-harm 
assessment using data from the MUST trial that compared corticosteroid implant versus 
systemic corticosteroids in non-infectious intermediate, posterior, and panuveitis. We 
calculated benefit-harm metrics to reflect the benefit-harm balance that took into account 
the treatment effects on different patient-centered outcomes and the patient preferences 
for these outcomes (derived from the preference-elicitation survey). The benefit-harm 
metrics at 6, 12, 18, and 24 months follow-up were all negative and the probabilities of 
the metric being positive were small or 0%. This implied that implant therapy had a 
worse benefit-harm balance than systemic therapy.        
 In summary, using an example of corticosteroid therapy for treating non-
infectious uveitis, we demonstrated a patient-centered approach to benefit-harm 
assessment where we focused on patient-centered outcomes and incorporated patient 
preferences to estimate treatment benefit-harm balance. Our approach can be applied in 
the future to different diseases and settings and help make evidence- and preference-
based treatment decisions.  
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 Making treatment decisions is difficult. The goal of treatments is to provide 
benefits, but they can come with harms. For example, aspirin is prescribed to patients to 
prevent cardiovascular diseases, but there is a risk of gastrointestinal and brain bleeds 
when taking aspirin.[1] Thus, it is not clear in whom aspirin would be beneficial overall 
so the benefits (lowered risk of cardiovascular diseases) outweigh the harms (increased 
risk of bleeds).[2] Patients and clinicians alike often face the uncertainty if a treatment is 
more beneficial than harmful to them or to their patients, or if it is worthwhile to bear the 
harms of a treatment in return for its benefits. Ideally, patients and clinicians involved 
should be well-informed of the available treatment options and their associated benefits 
and harms when they are faced with making treatment decisions.[3, 4] 
 
Not only do the patients and clinicians face the challenge of weighing benefits 
and harms in making treatment decisions, regulatory bodies also face the same challenge 
since their key task is to ensure that new medical products are safe and effective for use 
in the population.[5, 6] This requires the regulators to carefully assess the benefits and 
harms of drugs before making regulatory decisions. Any decision made by the regulatory 
bodies is dependent upon many factors including scientific results, uncertainties and 
subjective judgments.[6] The US Food and Drug Administration (FDA) has been 
criticized previously for not having enough clarity and transparency about their drug 
review process.[6] To address this issue, they made several commitments to developing 




 Previous research has proposed a number of approaches to benefit-harm 
assessment.[7-10] It can either be done qualitatively by informal synthesis of benefits and 
harms or instead quantitatively by building models that incorporate all data elements 
influencing the benefit-harm balance.[7-10] We argue here that using a quantitative 
approach to benefit-harm assessment is more explicit, consistent, and transparent than a 
qualitative assessment because all elements that go into the analysis are clearly laid out 
and because the impact of varying these elements can easily be assessed.[9] Thereby, it 
can provide a basis for decision-making and improve the communication between 
different stakeholders (e.g., patients, clinicians, and policy-makers).  
 
Critical elements for benefit-harm assessment 
 
 Many quantitative approaches to benefit-harm assessment were developed to 
synthesize three critical data elements in estimating the benefit-harm balance: treatment 
effects on outcomes, baseline outcome risks, and relative importance of outcomes.[9] 
Treatments are often evaluated in randomized clinical trials to learn their effects on 
multiple benefit and harm outcomes. When attempting to apply these treatment effects to 
a patient population, we need also to account for the baseline outcome risks, which are 
the background risks for outcomes if patients were not treated. As in the example of 
aspirin, prescribing aspirin to elder patients (who are at a higher risk for gastrointestinal 
bleeds) is likely to cause more gastrointestinal bleeds events than to younger patients 
(who are at a lower risk for gastrointestinal bleeds).[2] Moreover, different outcomes can 
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mean very differently to patients.[11] In conducting benefit-harm assessment, 
investigators often assign weights (relative importance) to outcomes when comparing 
different outcomes against each other. These weights can be informed by patient 
preferences but may vary depending on whose perspectives are of interest (e.g., patients’, 
clinicians’, or policy-makers’ perspective).[8] 
 
 Here we briefly give one example of a comprehensive benefit-harm assessment in 
which the investigators used absolute risks (number of events prevented or in excess) to 
assess the benefits and harms of Tamoxifen in preventing breast cancer (see Appendix 1-
1).[12] 
  
 Puhan and his colleagues have proposed a framework to organize and select 
different quantitative approaches to conducting benefit-harm assessment, which was 
based on the number of benefit and harm outcomes and whether a comparison metric is 
used.[9] Some approaches to benefit-harm assessment consider only a single outcome for 
benefits and a single outcome for harms and some approaches consider more than one 
outcome for benefits or harms. The metrics being used to compare the benefit and harm 
outcomes are different across approaches as well.[9] For example, some people use 
number needed to treat/number needed to harm (NNT/NNH) ratio[13, 14] and some use 
quality-adjusted life years (QALYs)[15] to synthesize different elements of a benefit-
harm assessment. A number of challenges that investigators may encounter while 
conducting the assessment were identified in previous reviews[7-10] and are summarized 
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in the Table 1-1. Two of the challenges are of main interest in this dissertation: selecting 
outcomes for benefit-harm assessment and assessing relative importance for treatment 
outcomes.  
 
Selecting outcomes for benefit-harm assessment 
 
 Selecting outcomes is one key step for a benefit-harm assessment because we 
want to capture the treatment effects that are meaningful to patients.[3, 4] We advocate 
that investigators should first consider patient-centered outcomes, instead of surrogate 
outcomes, for conducting their benefit-harm assessments. Surrogate outcomes, defined by 
Temple[16] as “a laboratory measurement or a physical sign used as a substitute for a 
clinically meaningful outcome that measures directly how a patient feels, functions or 
survives”, are commonly used in clinical trials to demonstrate treatment effects.[17] Low 
bone mineral density, for instance, is a surrogate outcome that is not immediately felt by 
patients or does not immediately affect the functioning of patients. Instead, it is a risk 
factor for fractures that represent a patient-centered outcome immediately linked to how 
patients function in everyday life.[18] 
 
 Surrogate outcomes may correlate well with the patient-centered outcomes that 
affect the health of patients but may not fully capture the effect of treatments.[19] 
Examples such as CD4 cell count and progression of AIDS,[20] tumor shrinkage and 
survival of cancer patients[21] and arrhythmias and sudden cardiac death[22] show that 
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use of surrogate outcomes in replacement of patient-centered outcomes may be 
misleading about the treatment effect.[23] Ideally, treatment effects on surrogate 
outcomes should have been shown to predict treatment effects on patient-centered 
outcomes before surrogate outcomes can be used in clinical trials.[24] For benefit-harm 
assessment, however, it is currently unclear how to include surrogate outcomes in the 
assessment. Moreover, if treatment effects are only evaluated for surrogate outcomes, 
how can investigators proceed? 
 
Assessing relative importance for treatment outcomes 
 
 Another key step in doing a benefit-harm assessment is to properly weigh the 
relative importance of treatment outcomes, which can be informed by patient 
preferences.[25] Patients value different health outcomes at different importance. An 
individual’s preference reflects the degree of their subjective satisfaction, distress or 
desirability for a given health outcome.[26, 27] The trade-offs between different benefits 
and harms of treatments is thus largely influenced by how patients place the relative 
importance on each outcome.[28] In the United States, the newly established Patient-
Centered Outcomes Research Institute aims to conduct research that engages more of the 
patients’ perspective, interests, and values with the hope that patients can make informed 




 Different methods have been used to assess patient preferences, e.g., ranking or 
rating, standard gamble (SG), time trade-off (TTO), and visual analogue scale (VAS).[29, 
30] The SG is an instrument based on a decision-making model that involves uncertainty, 
where participants are asked to choose either a gamble between perfect health and death 
or living in a given health state (an intermediate health state between perfect health and 
death).[30] The TTO, developed as an alternative to SG, is an instrument in which 
participants are asked to choose between two options: living in a certain health state for 
time t followed by death or living in perfect health for time x (x < t) followed by 
death.[30] Both SG and TTO are conceptually nice ways to assess patient preferences but 
are challenging for respondents and thus may preclude from obtaining reliable data.[31]   
  
 Another method to obtain patient preferences is the VAS, where participants are 
asked to assign their preference for a health state on a linear rating scale anchored by 
perfect health and death.[30] One limitation of VAS is that, unlike SG, it does not reflect 
conditions of uncertainty under which medical decisions are usually made. It also does 
not involve “trade-offs” while methods such as SG and TTO ask participants about trade-
offs between different health states.[30] These preference-elicitation approaches 
developed in health economics are helpful for us to understand how patients make trade-
offs between efficacy and safety and to better use evidence from clinical trials or 
epidemiologic studies to make treatment decisions.[32] However, the challenging tasks of 




 Best-worst scaling (BWS) method may address this operational challenge. It is 
another type of preference-elicitation approach that was designed in marketing research 
and has gained popularity in recent years in healthcare research.[33-36] In BWS, 
participants are presented with different sets of “objects”, and then they are asked to 
select the best and the worst objects in each set. The importance of an object relative to 
others (preferences) can be inferred statistically from a series of stated choices that 
participants make in the BWS tasks (see Appendix 1-2 for details). BWS has been shown 
to be a less cognitively demanding approach to eliciting preferences; thus, it has a great 
potential for use in the clinical settings.[33] 
 
The clinical example: uveitis and corticosteroid therapy 
  
 In this dissertation, we will illustrate our approach to benefit-harm assessment 
with the example of corticosteroid therapies for treating non-infectious uveitis.  
 
Uveitis includes a wide range of clinical conditions where inflammation affects 
components of the uvea, i.e., the iris, ciliary body, and choroid. The classification system 
recommended by the International Uveitis Study Group and the Standardization of 
Uveitis Nomenclature working group is based on the anatomical location.[37, 38] They 
categorized uveitis into four types: anterior, intermediate, posterior, and panuveitis. 
Uveitis can also be categorized on the basis of its onset, duration, and course. Causes of 
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uveitis include microbial infection, trauma, and autoimmunity but the cause remains 
unknown in many cases.[39] 
 
 Non-infectious uveitis can cause vision loss and accounts for around 10% of 
blindness in the United States.[40] Adults aged from 20 to 60 years are more often 
affected by uveitis than other age groups.[41] Thus, compared to other age-related eye 
diseases such as cataracts, glaucoma, and age-related macular degeneration, uveitis has a 
disproportionately high socioeconomic impact because it affects mainly the working 
population.[42] The goal of treating uveitis is to eliminate the inflammation within the 
eye to preserve patients’ vision while minimizing the potential harms associated with the 
treatments. 
 
 Corticosteroid usage is the primary treatment for uveitis. This group of 
medications has strong anti-inflammatory and immunosuppressive effects. The modes of 
delivery of corticosteroids include topical, periocular, intravitreal, and systemic routes. 
Topical corticosteroids are used mainly for anterior uveitis because they cannot penetrate 
the posterior segment well to achieve the necessary concentrations for intermediate or 
posterior uveitis.[43] Periocular corticosteroid injections are effective in treating 





 Corticosteroids can also be delivered intravitreally by injection of corticosteroids 
into the vitreous body[45] or by implantation of sustained-release delivery vehicles, e.g., 
Ozurdex
®
 (Allergan, Inc., Irvine, CA, USA) and Retisert
®
 (Bausch & Lomb, Rochester, 
NY, USA).[46] The sustained-release implant releases corticosteroids over a period of 
time (months to years) and has been found to be effective in non-infectious uveitis 
patients.[47] Systemic (oral) corticosteroids are often used in patients with intermediate 
and posterior uveitis that is bilateral or related to systemic diseases, or in patients poorly 
responsive to topical and periocular corticosteroids.[47] When corticosteroids are used in 
a local (topical, periocular, and intravitreal) way, the systemic side effects associated oral 
corticosteroid therapy can be limited. However, the risks of developing cataracts and 
elevated intraocular pressure or glaucoma are much higher.[48] 
 
The Multicenter Uveitis Steroid Treatment Trial 
  
 In 2004, the National Eye Institute funded the study of the Multicenter Uveitis 
Steroid Treatment (MUST) Trial,[49, 50] which is a comparative effectiveness clinical 
trial comparing local fluocinolone acetonide implant therapy with systemic 
corticosteroids plus immunosuppression when indicated (current standard of care) for 
non-infectious intermediate, posterior, and panuveitis. The aim of the MUST Trial was to 
determine if the implant therapy is better than the systemic therapy in terms of the 
effectiveness and safety. Two hundreds and fifty-five patients for whom systemic 
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corticosteroids were indicated were randomized. Change in best-corrected visual acuity 
from baseline to 24 months was defined as the primary outcome in the trial. 
  
 At 24 months follow-up, results of the MUST Trial showed that the improvement 
in visual acuity between the implant therapy group and the systemic therapy group was 
not statistically significantly different (6.0 versus 3.2 letters, p=0.16). The implant 
therapy group showed a better control of uveitis activity during follow-up (88% versus 
71% controlled at 24 months, p=0.001). However, the implant group had a higher risk of 
developing cataracts (91% versus 45 %; hazard ratio=4.1, p<0.0001) or glaucoma (17% 
versus 4.0%; hazard ratio=4.2, p=0.0008). The risk of adverse systemic outcomes 
(including systemic infections, hypertension, hyperlipidemia, etc.) was generally lower in 
the implant therapy group although most effects were not statistically significant. The 
investigators of the MUST Trial concluded that “the specific advantages and 
disadvantages identified should dictate selection between the alternative treatments in 
consideration of individual patients’ particular circumstances.”[50] This indicates that 
there is still much uncertainty about the use of fluocinolone acetonide implant for patients 
with non-infectious uveitis given its associated harms. 
  
 Findings from the MUST Trial therefore provided us with a great opportunity to 
investigate new approaches to benefit-harm assessment, because each treatment strategy 
was associated with treatment outcomes that occurred at different frequencies and that 
had various importance to patients. It is perhaps impossible or challenging, without using 
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a structured and quantitative approach, to properly synthesize all these elements to learn 
the treatment benefit-harm balance. Ideally, such an approach will clearly define the 
treatment outcomes of interest, assess patient preferences (relative importance) for 
outcomes and synthesize the treatment effects on outcomes with their relative importance 
to facilitate the comparison between treatments and thereby help make evidence- and 
preference- based decisions.[9] 
 
Overview of the dissertation 
  
 The overarching goal of this dissertation was to develop a patient-centered 
approach to benefit-harm assessment that focuses patient-centered outcomes and that 
considers patient preferences. Using a clinical example, we quantitatively assessed the 
benefits and harms of two treatment strategies in non-infectious uveitis to learn their 
benefit-harm balance. At the same time we demonstrated how incorporating patients’ 
perspectives can be achieved in medical research. Chapter 2 is a survey of the drug 
approvals by the US FDA to examine how surrogate outcomes were dealt with when they 
were assessing the benefits and harms of a drug, and accordingly we developed a 
framework for selecting outcomes in benefit-harm assessments. Chapter 3 is a patient 
preferences study in which we used BWS approach to elicit outcome preferences by 
surveying patients with non-infectious uveitis. We obtained the relative importance of the 
six treatment outcomes, as perceived by patients. Chapter 4 is a quantitative benefit-
harm assessment that is based on a comparative effectiveness trial (the MUST Trial) 
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comparing corticosteroid implant versus systemic corticosteroids in non-infectious 
uveitis. We focused on patient-centered outcomes and incorporated patient preferences in 
our assessment. Finally, in Chapter 5, we summarized our findings of the dissertation 
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Benefits and harms vary depending on the 
characteristics of the disease, population, intervention 
and comparison. 
Selecting outcomes  Surrogate outcomes are often reported in some diseases 
and they may not fully substitute for patient-centered 
outcomes. 
Suboptimal reporting on harm outcomes. 
A single benefit and a single harm outcome, or multiple 
benefit and harm outcomes need to be considered in the 
analysis. 
Defining time frames Benefits and harms occur at various time points (e.g., 
early benefits but late harms). 
Assessing quality of the 
evidence 
The evidence on benefits and harms is obtained from 
studies with various qualities. 




The weight (relative importance) of outcomes is 
considered differently by different stakeholders.  
Choosing comparison 
metrics 
Whether to put the benefits and harms on the same 






Appendix 1-1. An example of quantitative benefit-harm assessment: Tamoxifen for 
preventing breast cancer 
 Gail and his colleagues in the National Cancer Institute developed an approach to 
benefit-harm assessment that can deal with the situation when treatments are associated 
with multiple outcomes.
1
 Use of Tamoxifen in women can reduce the risk of breast 
cancer and bone fractures; however, it also increases the risk of endometrial cancer, 
stroke, and pulmonary embolism. In Gail’s quantitative assessment, they first estimated 
in a cohort of women, the risk of different outcomes with treatment and without treatment 
using evidence from observational studies (baseline outcome risks) combined with 
clinical trials (treatment effects). They calculated, both with and without Tamoxifen 
treatment, the number of different outcomes expected per 10000 women over five years, 
stratified by different age and race. Then, they computed treatment “benefits” as number 
of events prevented and “harms” as number of events in excess. For instance, for white 
women aged 40-49 years with 2.0% 5-year risk of breast cancer, with the use of 
Tamoxifen, 97 cases of breast cancer will be prevented but 16 cases of endometrial 
cancer will be in excess per 10000 women over five years. Finally, in order to put 
multiple outcomes on the same metric, they assigned a weight to each outcome according 
to its clinical importance (e.g., 1 for life threatening, 0.5 for severe, and 0 for others), and 
presented the results as a net number of events prevented or in excess per 10000 women. 
                                                            
1 Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and 
benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829-46. 
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By conducting the benefit-harm assessment, they were able to identify the women’s risk 
profiles for which Tamoxifen is most beneficial.  
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Appendix 1-2. Best-worst scaling 
 Best-worst scaling (BWS) is an approach to eliciting consumer preferences and 
includes 3 different types (cases): Case 1 (object case), Case 2 (profile case), and Case 3 
(multi-profile case).
2
 Case 1 BWS is the simplest form, in which individuals are asked 
each time to choose the top and bottom ranked ones (“best” and “worst”) from a list of 
“objects”. In this dissertation, we are interested in, from patients’ perspective, the relative 
importance of 6 outcomes, so these 6 outcomes comprise our list of 6 objects. Often in 
each BWS task a set of these objects (e.g., 3 out of 6 outcomes), instead of all 6, is 
presented to individuals. Individuals are asked to complete repeated BWS tasks that are 
made up of different choice sets. Balance Incomplete Block Design is the design 
commonly used to generate the different choice sets. This design ensures that the 
occurrence and co-occurrence of objects across BWS tasks are constant. In our example, 
in each BWS task there are 3 outcomes for comparison, and individuals are asked to 
complete 10 BWS tasks. 
 BWS data can be analyzed using the “best minus worst score”. For each object in 
a BWS study, we can calculate the number of times an object is chosen as “best” minus 
the number of times an object is chosen as “worst”. This best minus worst score was 
found to have a linear relationship with the maximum likelihood estimates of the 
                                                            





conditional logit model, another approach to analyze BWS data.
3
 One major advantage of 
using the best minus worst score for analysis is that it can help understand the choice data 
at individual level and thus facilitates exploring heterogeneity.
4
  
                                                            
3 Marley AAJ, Louviere JJ. Some probabilistic models of best, worst, and best-worst choices. Journal of 
Mathematical Psychology. 2005;49:464-480. 
4 Auger P, Devinney TM, Louviere JJ. Using best-worst scaling methodology to investigate consumer 












USE OF SURROGATE OUTCOMES IN FDA DRUG APPROVALS 
 






To evaluate how often surrogate outcomes are used as a basis for drug approvals 
by the US Food and Drug Administration (FDA) and whether and how the rationale for 
using treatment effects on surrogates as predictors of treatment effects on patient-
centered outcomes was discussed.  
Study design and Setting 
 We used the Drugs@FDA website to identify drug approvals produced from 2003 
to 2012 by FDA. We focused on four diseases (chronic obstructive pulmonary disease 
(COPD), type 1 or 2 diabetes, glaucoma, and osteoporosis) where surrogates are 
commonly used in trials. We reviewed the drug labels and medical reviews. 
Results 
 Of 1043 approvals screened, 58 (6%) were for the four diseases of interest. Most 
drugs for COPD (7/9, 78%), diabetes (25/26, 96%) and glaucoma (9/9, 100%) were 
approved based on surrogates while for osteoporosis, most drugs (10/14, 71%) were also 
approved for patient-centered outcomes (fractures). The rationale for using surrogates 






 Our results suggest that the FDA did not use a consistent approach to address 
surrogates in assessing benefits and harms of a drug. We proposed a framework for the 





 The goal of treatments is to provide benefits to patients but at times treatments 
come with harms. For example, aspirin is prescribed for preventing cardiovascular 
diseases, but it is associated with an increased risk of gastrointestinal bleeds [1]. Thus, a 
comprehensive benefit-harm assessment is required to determine in which populations 
aspirin will have more benefits than harms [2, 3]. Benefit-harm assessment is also a key 
task for regulatory agencies because a new drug must be proven efficacious and safe for a 
specific indication before marketing [4]. The United States Food and Drug 
Administration (US FDA) and the European Medicines Agency (EMA) have both 
recognized the need to have a more structured and transparent approach to benefit-harm 
assessment that will inform the drug approval process for both agencies [5, 6]. Such an 
analysis begins by defining the decision-making context, including the appropriate 
population(s), intervention(s), comparison(s), outcome(s), and timeframe(s). Then, the 
drug reviewers conduct a quantitative analysis of treatment effects on different benefit 
and harm outcomes to make an overall assessment of the evidence. When doing benefit-
harm assessment, selecting patient-centered outcomes, i.e., outcomes that patients notice 
and care about (survival, function, symptoms, and health-related quality of life) will 
make the results more informative to patients and other stakeholders [2, 7]. 
 
 One major challenge of conducting a benefit-harm assessment is that surrogate 
outcomes are often used in randomized clinical trials (RCTs) to demonstrate the 
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treatment effects, without assessing patient-centered outcomes [8, 9]. A surrogate 
outcome is a biomarker or an intermediate to a patient-centered outcome that is “expected 
to predict clinical benefit (or harm or lack of benefit or harm)” [10]. The International 
Conference on Harmonisation issued guidelines for the conduct of clinical trials for the 
registration of drugs (ICH-9) that described a hierarchy of evidence for surrogacy [11]. In 
general, the evidence for surrogacy may come from pathophysiologic studies suggesting 
the biological plausibility of the association between surrogate outcomes and patient-
centered outcomes, or from observational studies demonstrating the association between 
them. The highest level of evidence requires that RCTs have shown the treatment effects 
on surrogate outcomes can predict the treatment effects on patient-centered outcomes. 
The use of treatment effects on only surrogate outcomes for regulatory and clinical 
decision-making purposes remains commonplace regardless of the evidence supporting 
the validity of the surrogates [12, 13]. 
  
 For prescription drugs treating certain diseases, surrogate outcomes were found to 
be used as primary outcome in about 50% of pivotal trials for regulatory approval [14]. 
For example, change in intraocular pressure (IOP) is often the primary outcome for RCTs 
on glaucoma medications instead of more direct measures of glaucoma such as optic disk 
deterioration or vision loss [15]. Another example is diabetes. Gandhi et al.[16] found 
that in 436 registered RCTs in type 1 or 2 diabetes, only 78 (18%) trials chose patient-
centered outcomes as primary outcomes. Most trials used glycated hemoglobin to test the 
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efficacy of diabetes interventions instead of assessing their effects on clinical outcomes 
that have direct effects on patients’ symptoms, function, and quality of life such as 
cardiovascular events. Some argue that the regulatory pathway of diabetes interventions 
relies too heavily on surrogates and should require patient-centered outcomes as well 
[17]. 
 
 It is currently unclear if the FDA uses a consistent approach to address surrogate 
outcomes for drug approvals. A critical question is if the FDA review addresses whether 
treatment effects on surrogate outcomes predict the treatment effects on patient-centered 
outcomes across a spectrum of diseases. Our aim was to review the drug approvals for 
four diseases produced by the US FDA from 2003 to 2012 to learn how often these 
approvals were based on surrogate outcomes, and whether and how the rationale for 
using surrogate outcomes was discussed. 
 
METHODS 
Selection of drug approvals 
 We used the Drugs@FDA website 
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm) to identify all drug 
approvals produced from January 2003 to December 2012 (n=1043) by the US FDA. 
Drugs@ FDA is an open access database for drug products approved by the FDA that 
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contains a drug approval package, including information on drug labels, approval letters 
and reviews such as medical, chemistry, pharmacology, and statistical reviews. These 
reviews provide scientific analysis of a drug product and explain the FDA’s thinking for 
the approval decision. Two authors (TY and YJH), working independently, screened the 
list to select the approvals that were eligible. The inclusion criteria were drug approvals 
where the drugs are indicated for the treatment of chronic obstructive pulmonary disease 
(COPD), diabetes, glaucoma, or osteoporosis. We focused on these four diseases because 
surrogate outcomes (lung function for COPD, blood sugar level for diabetes, IOP for 
glaucoma, and bone mineral density for osteoporosis respectively) are commonly used as 
primary outcomes in RCTs and all of them are “well established” surrogates for patient-
centered outcomes [15, 18-20]. We excluded the drugs that are only indicated for a 
specific symptom related to the diseases or indicated for a specific patient population. 
Thus, we excluded a glaucoma drug that is indicated as an adjunct to ab externo 
glaucoma surgery, a diabetes drug approved for treating adult patients with endogenous 
Cushing’s syndrome who have type 2 diabetes, and a drug treating diabetic peripheral 
neuropathic pain. We also removed any duplicate records. If there was a disagreement 








 During the drug’s approval process, the FDA review team will critically evaluate 
the drug’s benefits and harms in different aspects and produce review documents, 
including the medical, chemistry, pharmacology, and statistical reviews, etc. For each 
included drug approval we retrieved the drug labels and medical reviews that were 
available on the Drug@FDA website. We focused on medical reviews instead of other 
reviews because medical reviews are, as we learned during pilot-testing of data 
extraction, most likely the review documents where the FDA reviewers address the issue 
of outcome selection. In addition, the medical review documents provide the FDA 
reviewers’ assessment of clinical evidence that establishes the efficacy and safety of the 
drug. We developed and pilot-tested a standardized form for data extraction. Using the 
documents of drug labels and medical reviews, we extracted the information on 
indications and the primary outcomes that the indications were based on. We categorized 
these outcomes into a surrogate outcome or a patient-centered outcome, using the 
definition mentioned previously. For each drug approved based only on surrogates, we 
examined if the rationale for using surrogate outcomes was discussed or not (yes/no). We 
also assessed whether the surrogate was identified as being based on the highest level of 
evidence for surrogacy using the ICH-9 criteria, which is that the treatment effects on 
surrogates predict treatment effects on patient-centered outcomes. Two authors (TY and 
YJH) independently reviewed all documents and extracted the data. The discrepancies 
between authors on outcomes and the rationale for using surrogates outcomes were 
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 Sixty-eight out of 1043 (7%) drug approvals were about COPD, diabetes, 
glaucoma or osteoporosis, and 58 (58/1043; 6%) of these were eligible for our study. The 
reasons for exclusion of approvals are summarized in Figure 2-1. Out of the 58 included 
approvals, 9 were for COPD (16%), 26 (45%) for diabetes, 9 (16%) for glaucoma, and 14 
(24%) for osteoporosis. For three of the four examined conditions, the drug approvals 
were mostly based only on a surrogate outcome (COPD (7/9 approvals were based only 
on a surrogate, 78%), diabetes (25/26 approvals, 96%), and glaucoma (9/9 approvals, 
100%) (Table 2-1). COPD drug approvals were primarily based on the effects on 
improving lung function, with the exception of two drug approvals (SPIRIVA 
HANDIHALER and DALIRESP) that also examined COPD exacerbations. Almost all 
diabetes drug approvals were based on lowering blood sugar level except for one drug 
approval (JUVISYNC), which included patient-centered outcomes (mortality and 
cardiovascular events) as well. Glaucoma drug approvals were all based on lowering IOP. 
Most drug approvals for osteoporosis (10/14; 71%) were based on both surrogate 




 Among the drugs that were approved based only on surrogates, 11 (11/43, 26%) 
of them discussed in the medical review the rationale for using surrogate outcomes to 
demonstrate drug efficacy for regulatory approval (Table 2-2). For COPD drug approvals 
based on surrogates, a medical review for one drug (TUDORZA PRESSAIR) mentioned 
the limitations of using lung function and the importance of evaluating patient-centered 
outcomes such as COPD exacerbations. For glaucoma, the reviews for three drugs 
(ALPHAGAN P, QOLIANA, and LUMIGAN) discussed the rationale for using change in 
IOP for drug approval. These reviews mentioned the association between high IOP and 
visual function loss but did not cite evidence from RCTs that an effect on IOP predicts an 
effect on visual function. For diabetes, we found that the reviews for seven drugs 
(APIDRA, SYMLIN, EXUBERA, JANUVIA, JANUMET, VICTOZA, and BYDUREON) 
discussed the rationale for use of surrogates and three of them (SYMLIN, VICTOZA, and 
BYDUREON) justified choosing glycemic control as an outcome by citing evidence from 
trials that corresponds to the highest level of evidence for surrogacy using the ICH-9 
criteria. Specifically, they cited evidence that the treatment effect on blood glucose level 
can predict treatment effects on micro- or, to a lesser extent, macro-vascular 
complications. For example, in the review of VICTOZA, the reviewer stated that “HbA1c 
has excellent reliability, predicts several diabetes-specific complications, and provides 
the current basis for treatment decisions. Lowering HbA1c reduces microvascular 
complications in patients with type 1 and type 2 diabetes and possibly macrovascular 





 Our findings suggest that the FDA did not use a consistent approach to address 
surrogate outcomes when reviewing the drug approvals included in this study. Thus, the 
drug approvals are not consistently transparent about the role surrogate outcomes play in 
the drug approval process. For COPD, diabetes, and glaucoma, new drugs are often 
approved based on treatment effects on surrogate outcomes. But for osteoporosis, 
treatment effects on the surrogate outcome (bone mineral density) and the patient-
centered outcome (fractures) are often examined together when regulatory decisions are 
made. The rationale for using surrogate outcomes for drug approval was not always 
discussed. If it was discussed, drug approvals for diabetes are more likely than drug 
approvals for the other examined conditions to contain a discussion of RCT evidence that 
demonstrates treatment effects on surrogate outcomes (blood sugar level) predict 
treatment effects on patient-centered outcomes (macro- or micro-vascular events). 
  
 Surrogate outcomes are sometimes chosen as the primary outcomes when 
designing the RCTs because they have the advantages of saving time, sample size, and 
resources in order to show a particular effect size compared to patient-centered outcomes 
that may take longer to accrue and require larger samples and longer studies [8]. In our 
survey, we found that in COPD, glaucoma, and diabetes, RCTs using surrogate outcomes 
also form the basis of drug approvals that were made by the FDA. The use of surrogate 
outcomes in RCTs, however, may complicate the benefit-harm assessment of treatments. 
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Surrogate outcomes are often captured using laboratory measurements, such as lung 
function for COPD, blood sugar level for diabetes and IOP for glaucoma. To calculate a 
benefit-harm metric like number needed to treat (NNT) or number needed to harm 
(NNH) [21], it is necessary to dichotomize the outcome variable to define a clinically 
meaningful change. For example, the target level for glycemic control is often set as 
hemoglobin A1C <7% in adult patients with type 2 diabetes mellitus, which is a level of 
hemoglobin A1C that has been linked to a lower risk of micro- or macro-vascular events 
[22]. However, using a threshold as an outcome is increasingly controversial because 
surrogates may have a continuous and non-linear relationship to the corresponding 
patient-centered outcomes [23]. Ideally, we would have treatment evidence on outcomes 
that are directly relevant to patients. RCTs should provide us direct evidence on how 
much a new diabetes drug lowers the risk of patient-centered outcomes such as stroke or 
amputation, and what side effects it causes to patients. Decision makers can then be better 
informed of whether or not treatment benefits outweigh the harms. 
    
For the diseases we examined, FDA guidance documents provided guidelines for 
industry to design RCTs for regulatory approval [15, 18-20]. For COPD, diabetes, and 
glaucoma, the FDA allows using surrogate outcomes for drug approvals. For example, 
most glaucoma drugs are now indicated for “lowering IOP” but are not indicated for 
“treating glaucoma” (e.g., slowing glaucoma disease progression) [15]. Only the FDA 
guidance document for osteoporosis clarified that patient-centered outcomes (fractures) 
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are required for some classes of drugs to be approved for treating osteoporosis, because 
the association between increasing bone mineral density and lowering fracture risk has 
been shown to be inconsistent across trials [19, 24]. Hence, most approvals for 
osteoporosis drugs included in our study examined evidence on both bone mineral 
density and fractures. 
  
We suggest that applications for almost all drugs should try to include direct 
evidence of the treatment effect on patient-centered outcomes. One may argue that it is 
not always practical to choose patient-centered outcomes as the primary outcome in 
RCTs because the events are too rare and the time period is too long to conduct the trial. 
It is thus unlikely that we will have data on patient-centered outcomes in every trial. If it 
is inevitable to use evidence on surrogate outcomes for drug applications, drug reviewers 
should at least review the level of the evidence for surrogacy (e.g., based on the ICH-9 
criteria) when they are assessing the drugs’ benefits and harms, and drug reviewers 
should also consider if the evidence for surrogacy is still relevant for the specific 
treatment and population under review. 
 
For example, Staessen et al.[25] reviewed antihypertensive clinical trial data and 
examined the relationship between treatment effects on systolic blood pressure and 
treatment effects on cardiovascular events by drug class. Such a review can serve as the 
source for evidence for surrogacy when assessing treatment benefits and harms. In our 
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study samples, the number of drug approvals that provided the rationale for use of 
surrogate outcomes was lower than we expected and only some of them cited evidence 
from RCTs that evaluated the surrogates. It might be that the FDA concluded in prior 
drug approvals that the surrogate outcomes were valid and the rationale was provided 
(before 2003). At a minimum, FDA reviewers should cite those prior approvals. It would 
also be worthwhile for drug reviewers to address the evidence for a specific surrogate to 
be used for the drug and in the population under review. Further, quantifiable 
assumptions of surrogate effects on clinical outcomes will allow more valid and 
interpretable benefit-harm assessment of new drugs and also ease the communication of 
benefits and harms with patients and clinicians. Such an approach will provide greater 
transparency. 
 
A proposal for a framework for use of surrogate outcomes in patient-centered benefit-
harm assessment 
Here we propose a framework (see Figure 2-2) for use of surrogate outcomes in 
patient-centered benefit-harm assessment: 
 
 This framework asks four questions. The 1
st
 question in the framework is “What 
are the corresponding patient-centered outcomes?” It is important at first to be clear 
about which patient-centered outcomes the surrogate outcomes substitute for. If we could 
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use patient-centered outcomes in the benefit-harm assessment, what outcomes would be 
most relevant for the decision-making context? Then, the 2
nd
 question in the framework is 
“Are the corresponding patient-centered outcome data available?” Data on surrogate 
outcomes and patient-centered outcomes can be both available to investigators. As we 
have described earlier for RCTs comparing treatments for osteoporosis, there are often 
data available on fracture events and bone mineral density. However, it has been shown 
that the association between increasing bone mineral density and lowering fracture risk is 
inconsistent [24]. Since data on facture events are available in trials, we can use this 
information and do not need to use data on bone mineral density. We suggest that if data 
on patient-centered outcomes are available, then they should be considered primary 
because they are the actual outcomes of interest and there seems no reason to use 
information from surrogate outcomes that may only partially capture the corresponding 
patient-centered outcomes. 
  
 If there are no patient-centered outcome data, we propose to ask the 3
rd
 question 
“What is the evidence supporting the use of surrogate outcomes as a substitute for 
patient-centered outcomes?” To answer this question, we need to critically evaluate 
surrogate outcomes. The ICH-9 hierarchy of evidence can provide a framework for 
evaluation of surrogacy. Ideally, the evidence is based on RCTs that demonstrate the 
treatment effects on surrogate outcomes predict the treatment effects on patient-centered 
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outcomes. Moreover, one can conduct a systematic review, as Staessen et al.[25] did for 




 and the last question is “Can the evidence for surrogacy be applied to the 
specific treatment and population under study?” Even for the drugs that show a 
beneficial effect on surrogate outcomes, they are still likely to have unintended harmful 
effects on the patient-centered outcomes. For example, considering rosiglitazone, studies 
showed that although this drug effectively lowered the blood sugar level in patients with 
diabetes, it increased the risk of cardiovascular events [17]. When reviewing evidence of 
surrogacy, we should carefully consider if the evidence has been shown for the same drug 
(or the same class of drugs) and if the evidence can be applied to the specific treatment 
and population under review. It is possible that the evidence may no longer be 
appropriate as the scientific understanding evolves, or there are new issues or concerns 
about the use of the surrogate in certain populations. 
  
 These four questions will help us conduct patient-centered benefit-harm 
assessment when most of the efficacy data are about surrogate outcomes. 
  
 There are a few other published guidelines for evaluating surrogate outcomes in 
clinical trials. For example, Prentice proposed the statistical criteria for surrogate 
43 
 
outcomes that require them to “capture any relationship between the treatment and the 
true endpoint” [26]. Bucher et al. published a guidance document for surrogate outcomes 
as part of JAMA Users’ Guides to the Medical Literature [27]. They proposed to ask 
several questions when addressing surrogate outcomes. First, evidence users should 
examine if the evidence supporting surrogate outcomes is valid; i.e., if there is a 
consistent association between treatment effect on the surrogate outcomes and treatment 
effect on the corresponding patient-centered outcomes. Second, evidence users should 
examine how “large, precise and lasting” of the treatment effect is on surrogate outcomes 
of interest. Finally, evidence users should assess if the treatment benefits caused by the 
change in surrogate outcomes outweigh the harms and costs to patients. Our framework 
agrees with what was proposed previously and we put more emphasis on the use of 
surrogate outcomes in the context of treatment benefit-harm assessment. We emphasize 
that patient-centered outcomes should be considered the primary data source in a benefit-
harm assessment. When the use of surrogate outcomes is necessary, it is also important to 
review the evidence for surrogacy and consider if the evidence is still relevant for the 
specific treatment and population under review. 
  
 This study has limitations. We only focused on the surrogate outcomes used for 
drug efficacy and did not include surrogate outcomes that substitute for harms. Harmful 
events are often rare, so regulatory agencies may require evidence from studies beyond 
RCTs such as large and long-term post-marketing studies. We reviewed four diseases 
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where surrogate outcomes are commonly used but did not review diseases such as 
cancers or HIV where the use of surrogate outcomes is also prevalent. The validity of 
surrogate outcomes will vary by disease, and potentially by drug (or class of drugs) and 
by sub-population as well [8, 28, 29]. We did not evaluate the new drug applications that 
were declined by the FDA because these documents are not publicly available. There 
may be more explicit analysis of surrogate outcomes in those documents. We focused on 
medical reviews of the FDA drug approval process since we found that this is where a 
discussion of surrogate outcomes would most likely be documented but there is the 
possibility that it was mentioned somewhere else in the FDA reviews. Finally, not 
documenting the rationale for use of surrogate outcomes does not mean that the FDA 
reviewers did not take it into account when making decisions. However, a documented 
discussion of the evidence will certainly increase the transparency of the process in which 
regulatory bodies consider surrogate outcomes for drug approvals. 
 
 In conclusion, our findings suggest that for many chronic diseases, drugs are 
approved based on their treatment effects on surrogate outcomes, but that the FDA does 
not use a consistent approach for surrogates in order to evaluate these drug applications. 
This makes it difficult to assess and interpret their actual clinical effects relevant to 
patients. To conduct a patient-centered benefit-harm assessment, we should select 
patient-centered outcomes whenever possible. If the use of surrogate outcomes is 
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necessary, reviewing the evidence for surrogacy and considering its application in the 
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Figure 2-1. Review process 
1043 Drug@FDA Drug Approvals 
(from 2003 to 2012)
68 reports on COPD, diabetes, 
glaucoma, and osteoporosis 






7 on the same drugs
1 drug is an adjunct to ab externo glaucoma surgery
1 drug is to treat adult patients with endogenous  
Cushing’s syndrome who have type 2 diabetes
1 drug is to treat diabetic peripheral neuropathic pain
975 excluded :




Figure 2-2. Framework for use of surrogate outcomes in patient-centered benefit-harm assessment 
Surrogate outcomes
Q1. What are the corresponding patient-centered outcomes?
Q2. Are the corresponding patient-centered outcome data available?
Q3. What is the evidence supporting the use of surrogate 
outcomes as a substitute for patient-centered outcomes?
Q4. Can the evidence for surrogacy be applied to the specific 
treatment and population under study?
No 



























Table 2-2. Rationale for using surrogate outcomes discussed in drug medical reviews (n=11) 
Disease Drug name Year 
approved 
Rationale for using surrogate outcomes The rationale is based on that 
“treatment effects on the 
surrogate outcome predict 
treatment effects on the 
patient-centered outcome” 
(highest level of evidence using 
ICH-9 criteria for surrogacy). 
COPD TUDORZA 
PRESSAIR 
2012 “Overall, the committee’s view was that the 
Applicant’s data for the primary endpoint of 
trough forced expiratory volume in one second 
(FEV1) demonstrated statistical significance, and 
that these results were clinically 
meaningful…Comments were made that the 
results for other measures of efficacy (e.g., the 
St. George’s Respiratory Questionnaire [SGRQ] 
and COPD exacerbations), while generally not 
statistical significant, were nonetheless trending 
in a direction to support the results for the 
primary endpoint…Several comments were made 
regarding the limitations of FEV1-based 





Disease Drug name Year 
approved 
Rationale for using surrogate outcomes The rationale is based on that 
“treatment effects on the 
surrogate outcome predict 
treatment effects on the 
patient-centered outcome” 
(highest level of evidence using 
ICH-9 criteria for surrogacy). 
Diabetes 
(type 1 or 
2) 
 
APIDRA 2004 “GHb (glycosylated hemoglobin) results were 
reported as glycated hemoglobin A1c (HbA1c) 
equivalents and are directly traceable to the 
Diabetes Control and Complications Trial (DCCT) 
reference, for which the relationship between 
mean BG (blood glucose) (measured by HbA1c) 




(type 1 or 
2) 
 
SYMLIN 2005 “That a reduction in HbA1c over 6-12 months 
can be associated with progression of diabetic 
retinopathy poses a regulatory dilemma. FDA 
(Food and Drug Administration) accepts 
reduction in HbA1c as a measure of efficacy in 
trials of new antidiabetic agents. This use of 
HbA1c as a surrogate endpoint reflects the 
finding that long-term reduction of HbA1c 





Disease Drug name Year 
approved 
Rationale for using surrogate outcomes The rationale is based on that 
“treatment effects on the 
surrogate outcome predict 
treatment effects on the 
patient-centered outcome” 
(highest level of evidence using 
ICH-9 criteria for surrogacy). 
Diabetes 
(type 1 or 
2) 
 
EXUBERA 2006 “An ideal trial would use diabetic complications 
as endpoints, but the trial size and duration 
needed for use of such endpoints would be very 
large. There is some controversy about whether 
HbA1c is truly a good marker of the risk for 
complications of diabetes. However, the 
correlation of HbA1c with risk for the 
development of microvascular disease in Type 1 
diabetics is well-established, and thus HbA1c is a 
good surrogate endpoint for the trials of inhaled 




JANUVIA 2006 “HbA1c is generally considered the most reliable 
surrogate of the glycemic control, and ultimately 
predicts late chronic complications of T2DM 
(type 2 diabetes mellitus) both microvascular 
and macrovascular, as demonstrated in the 
Diabetes Control and Complications Trial (DCCT) 





Disease Drug name Year 
approved 
Rationale for using surrogate outcomes The rationale is based on that 
“treatment effects on the 
surrogate outcome predict 
treatment effects on the 
patient-centered outcome” 
(highest level of evidence using 




JANUMET 2007 “HbA1c is generally considered the most reliable 
surrogate of the glycemic control, and ultimately 
predicts late chronic complications of T2DM 
(type 2 diabetes mellitus) both microvascular 
and macrovascular, as demonstrated in the 
Diabetes Control and Complications Trial (DCCT) 






VICTOZA 2010 “HbA1c has excellent reliability, predicts several 
diabetes-specific complications, and provides the 
current basis for treatment decisions. Lowering 
HbA1c reduces microvascular complications in 
patients with type 1 and type 2 diabetes and 





Disease Drug name Year 
approved 
Rationale for using surrogate outcomes The rationale is based on that 
“treatment effects on the 
surrogate outcome predict 
treatment effects on the 
patient-centered outcome” 
(highest level of evidence using 
ICH-9 criteria for surrogacy). 
with type 1 diabetes.” 
Diabetes 
(type 2) 
BYDUREON 2012 “HbA1c has excellent reliability, predicts several 
diabetes-specific complications, and provides the 
current basis for treatment decisions. Lowering 
HbA1c reduces microvascular complications in 
patients with type 1 and type 2 diabetes. There is 
weaker evidence showing that lowering HbA1c 
reduces macrovascular complications in patients 





2005 “Elevated IOP (intraocular pressure) presents a 
major risk factor in glaucomatous field loss. The 
higher the level of IOP, the greater the likelihood 




Disease Drug name Year 
approved 
Rationale for using surrogate outcomes The rationale is based on that 
“treatment effects on the 
surrogate outcome predict 
treatment effects on the 
patient-centered outcome” 
(highest level of evidence using 
ICH-9 criteria for surrogacy). 
Glaucoma QOLIANA 2006 “Elevated intraocular pressure is an etiological 
factor in glaucomatous cupping. Higher 
intraocular pressure corresponds with a greater 
frequency of optic nerve damage. Medical 
therapy for open-angle glaucoma is aimed at 
lowering the intraocular pressure below a level 
which is likely to produce further optic nerve 
damage.”  
Unclear 
Glaucoma LUMIGAN 2010 “Intraocular pressure (IOP) is currently the 
accepted standard for establishing the efficacy of 
ocular hypotensive medications. IOP is a 














PATIENTS WITH NON-INFECTIOUS UVEITIS CONSIDER 
IMPAIRED VISION, GLAUCOMA AND NEED FOR EYE SURGERY 
WORRYING ADVERSE TREATMENT OUTCOMES: RESULTS OF A 





 Local or systemic corticosteroid therapy in non-infectious uveitis is associated 
with different treatment outcomes. Little is known about how patients with non-infectious 
uveitis perceive the relative importance of these outcomes. We investigated and 
quantified patient preferences for outcomes using the best-worst scaling (BWS) 
approach. 
Methods 
 We administered a preference-elicitation survey to patients with non-infectious 
uveitis who were in the Multicenter Uveitis Steroid Treatment Trial Follow-up Study 
(MUST FS) and to patients with a history of non-infectious uveitis who were treated in 
uveitis clinics at 2 academic medical centers (Johns Hopkins University and University of 
Pennsylvania). Participants were asked to complete 6 visual analogue scale (VAS) tasks 
as a warm-up exercise followed by 10 BWS tasks. For each BWS task they selected the 
most and the least worrying out of 3 outcomes. Outcomes included in the survey were 
vision not meeting the requirement for driving, diagnosed with cataracts, diagnosed with 
glaucoma, needing eye surgery, needing medicine for high blood pressure/cholesterol, 






 Eighty-two patients in the MUST FS and 100 patients treated at the academic 
medical centers participated in the survey and provided valid responses for data analysis. 
According to BWS results, participants were more likely to select vision not meeting the 
requirement for driving (standardized individual BWS score: median = 80, interquartile 
range = 50 – 100), glaucoma (70, 60 – 90), and needing eye surgery (60, 50 – 80) as the 
most worrying treatment outcomes as compared against needing medicine for high blood 
pressure/cholesterol (30, 10 – 50), cataracts (30, 20 – 40), or infection (e.g., sinusitis) (20, 
0 – 50). In regression analyses, race and education were identified as the main factors that 
influenced patient preferences.  
Conclusions 
 Patients with non-infectious uveitis considered impaired vision, glaucoma and 
need for eye surgery worrying adverse treatment outcomes. Such preference data will 
provide important insights for making evidence- and preference- based treatment 




Results of the recent Multicenter Uveitis Steroid Treatment (MUST) Trial showed 
that both corticosteroid implant and systemic corticosteroids work to preserve vision for 
patients with non-infectious intermediate, posterior or panuveitis. But the MUST trial 
also indicated that each treatment is associated with different ocular and systemic adverse 
effects.[1, 2] A corticosteroid implant can be placed into a patient’s eye to deliver 
corticosteroids locally for the management of patients with non-infectious uveitis.[3] 
These implants were designed to reduce the need for systemic use of corticosteroids, 
which increases the risk for, e.g., high blood pressure and infections. However, studies 
have shown that use of the implants leads to a higher risk of developing cataracts and 
glaucoma.[2-4] Based on these results it is difficult to choose between corticosteroid 
implant or systemic corticosteroids because both treatments have varying advantages and 
downsides. 
 
Given that different treatments may lead to different outcomes, understanding 
how patients make trade-offs between these outcomes will substantially help inform 
benefit-harm assessments and treatment decisions.[5, 6] In a quantitative benefit-harm 
assessment, the aim is to compare treatments through a comprehensive assessment of 
treatment effects for multiple benefits and harms.[6] This method requires learning about 
patient preferences (i.e., the importance or weights that patients place on outcomes)[7] 
because the benefit-harm balance of treatments is sensitive to how patients value each 
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treatment outcome.[6, 8, 9] Besides benefit-harm assessment, preference data also play a 
key role in other health care research to inform policy, such as economic evaluation and 
decision analysis.[10, 11] Through incorporating patient preference data into these 
studies, research findings will reflect patients’ needs and support patient-centered 
care.[12, 13] 
 
The aim of our study was to learn how patients with non-infectious uveitis value 
treatment outcomes of corticosteroid implant and systemic corticosteroids by conducting 
a preference-elicitation survey. In addition, we explored whether patients’ characteristics 




We conducted a cross-sectional survey and used best-worst scaling (BWS), a 
technique introduced by Finn and Louviere in marketing research,[14] to elicit patient 
preferences. We chose a “Case 1” BWS design, in which a set of 3 or more “objects” are 
shown to participants, who are asked to indicate their preferences by choosing, for 
example, the best and worst objects.[15, 16] Through studying the probability that 
participants choose an object over others, we can elicit the preferences that participants 
have for that object. BWS has increasingly been applied in health care research and it is 
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deemed less cognitively burdensome to participants than most other preference-elicitation 
methods.[17]   
 
Patient Preferences Questionnaire 
 Through a literature review and consultation with investigators of the MUST 
Trial, we identified patient-centered treatment outcomes that are associated with 
corticosteroid implant and systemic corticosteroids regarding their use in non-infectious 
uveitis.[2, 18, 19] The main efficacy outcome was visual acuity and the main adverse 
outcomes included ocular events (cataracts, glaucoma, and eye surgery) and systemic 
events (hypertension, hyperlipidemia and systemic infections). We included 6 outcomes 
(see Table 3-1) in our preference-elicitation tasks and developed a description for each 
outcome with help from clinical experts and methodologists to make the wording as 
understandable as possible to patients. In our survey, we were interested in how patients 
on a group level make trade-offs between outcomes that are commonly seen in clinical 
practice. Some serious adverse events (e.g., endophthalmitis) are important to consider on 
an individual level when making treatment decisions but they are not as common so we 
decided to not include them in the list of outcomes. 
 
 The questionnaire started with asking participants to read the descriptions of the 6 
outcomes and complete a visual analogue scale (VAS) task for each outcome. These VAS 
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tasks were designed to serve as a warm-up exercise in the questionnaire to introduce 
participants to the outcomes before they proceeded with the BWS tasks. After 
participants read the description of each outcome, they assigned a score from 0 (least 
serious outcome) to 100 (most serious outcome) on a VAS to indicate how serious they 
perceive the outcome to be.  
 
Then the participants were asked to complete 10 BWS tasks. In each BWS, 3 
outcomes (“objects” in BWS) were shown to participants and they were asked to choose 
the one that would worry them most and the one that would worry them least. To cover 
all 6 outcomes equally in the 10 BWS tasks, we used a balanced incomplete block design, 
as recommended by experts,[15] to generate 10 sets of outcomes (3 outcomes per set). 
The balanced incomplete block design assures each outcome would appear as an option 
equally often (5 times, 3 × 10 ÷ 6) in the questionnaire and also co-appear with each other 
equally often. Using data from BWS tasks, the preference for a treatment outcome 
relative to the others can be inferred statistically according to a series of choices that 
participants make. We did pilot-testing of the questionnaire with clinicians and students 
to ensure that the instructions were clear. The questionnaire that we administered can be 






This study consisted of 2 populations of patients with non-infectious uveitis. For 
one population, 23 clinics in the Multicenter Uveitis Steroid Treatment Trial Follow-up 
Study (MUST FS) were contacted about their willingness to administer the Patient 
Preferences Questionnaire. Twelve clinics agreed to participate and administered the 
questionnaire to patients at their next scheduled follow-up visits between July 2013 and 
May 2014. The MUST Trial compared 2 active treatments, corticosteroid implant versus 
systemic corticosteroids, in patients with non-infectious intermediate, posterior and 
panuveitis. Details of its design and primary results can be found elsewhere.[1, 2] After 
the trial was concluded at 24 months after randomization, this cohort of patients has been 
followed for an additional 5 years for long-term treatment outcomes as part of the MUST 
FS. Institutional review boards (IRBs) at the coordinating center and at all 12 
participating clinical centers provided their approvals for the addition of the Patient 
Preferences Questionnaire. 
    
For the other population, outpatients with uveitis who were treated in ocular 
immunology clinics at the Sheie Eye Institute, University of Pennsylvania (referred to as 
PENN) or the Wilmer Eye Institute, Johns Hopkins University (referred to as JHU) were 
recruited. Between September 2013 and April 2014, patients at each clinic while waiting 
for their ophthalmologist appointment were contacted by study coordinators about their 
interest to complete the Patient Preferences Questionnaire. Inclusion criteria were 
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patients with a history of non-infectious anterior, intermediate, posterior or panuveitis 
and at least 18 years of age. Of note, we did not exclude patients with anterior uveitis 
although these patients are mainly treated with topical corticosteroids instead of 
corticosteroid implant or systemic corticosteroids. Because we believe that these patients 
also can contribute valid data on patient preferences for treatment outcomes. If patients 
agreed to participate and provided their oral consent, we administered the questionnaire 
to them and, additionally, asked 14 respondent-specific questions on their demographic 
information (e.g., age, gender, race, and education) and clinical characteristics (e.g., 
systemic comorbidities, vision, and experiences with treatments and outcomes). All study 
procedures were approved by IRBs at both institutions.  
 
Data Analysis 
 To analyze BWS data, we assigned a “+1” to the outcome chosen as the most 
worrying one and a “-1” to the outcome chosen as the least worrying one in each 
scenario. We computed an “individual BWS score” for each of the 6 outcomes (number 
of times an outcome was picked as the most worrying by a participant minus the number 
of times it was picked as the least worrying). In the questionnaire, each outcome appeared 
5 times across 10 BWS tasks. Thus, the individual BWS score for each outcome was on a 
scale bounded by -5 and +5, and the larger the score, the more worrying the outcome to 
the individual. Additionally, we counted the occurrence of best and worst choices across 
all participants to calculate the “aggregate BWS score” for each outcome. We chose to 
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analyze our data using BWS scores because BWS scores are easy to interpret and they 
have been shown to provide sufficient statistics for various regression models.[15] We 
were interested in learning if and how preference data elicited using the BWS method 
were different from that using the VAS method. Hence, to facilitate the comparison, we 
standardized the individual BWS scores on a 0-100 scale (same as the VAS scores). We 
constructed box plots of the standardized individual BWS scores and the VAS scores and 
ranked the outcomes based on the median of the scores. 
   
 We used simple linear regression to compare the 6 standardized individual BWS 
scores between the 2 populations (MUST FS vs PENN or JHU) and to explore the 
associations between each of the 6 BWS scores and patient characteristics that may 
influence their preferences (gender, age, race, education, time since diagnosis, location of 
uveitis, and experiences with treatment outcomes). To account for potential confounding, 
we constructed 6 multiple linear regression models with BWS scores of each outcome as 
the dependent variables, and in each model we adjusted for patient characteristics 
simultaneously. For each patient characteristic variable, we recognized that we were 
examining multiple associations between the variable and each of the 6 dependent 
variables. Thus, we applied Bonferroni correction to the statistical significance level (a p-
value of 0.05 divided by 6, 0.008) to minimize the problem of multiplicity when doing 
tests for significance. Analyses were conducted using SAS 9.3 (SAS Inc, Cary, NC) and 




Patient Characteristics  
As of July 2013, 210 patients were under follow-up in the MUST FS. Between 
July 2013 and May 2014, 89 patients across 12 MUST FS clinical centers completed the 
Patient Preference Questionnaire at their study visits. Seven patients did not provide valid 
responses on BWS tasks (in which the most and least worrying outcomes were not clearly 
indicated), and they were omitted from our analysis. Of the 82 patients included in our 
analysis, 36 were originally assigned to the implant therapy group and 46 to the systemic 
therapy group. Between September 2013 and April 2014, another 107 outpatients with 
non-infectious uveitis (73 from PENN and 34 from JHU) were also recruited for this 
study and 100 patients (68 from PENN and 32 from JHU) completed the questionnaire 
and provided valid responses. Taken together, our final analysis was based on responses 
of 182 patients with non-infectious uveitis. 
 
 The socio-demographic, disease, and treatment-related characteristics of the 182 
study participants are shown in Table 3-2. The majority of these 182 participants were 
female (74%), white (58%), employed with income (57%), and with high school graduate 
(30%) or some college education (29%). The mean age was 52 years (standard deviation 
15). The distributions of age and employment status were not significantly different 
between patients recruited from the MUST FS and patients recruited from PENN or JHU, 
but there were more male (15% vs 35%) and black (29% vs 44%) participants and more 
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people having high educational level (college graduate or higher: 24% vs 47%) in the 
latter population. The MUST trial did not include patients with anterior uveitis, while 
most patients we recruited from PENN or JHU were patients with a history of anterior 
uveitis (52%), who were less severe cases. Patients from the MUST FS were more likely 
to be bilateral (88% vs 72%), to have been diagnosed with uveitis for a longer time 
(median years: 10 vs 5), and to have more experiences with treatments including 
corticosteroid injections, systemic corticosteroids, and eye surgery. But their experiences 
with certain diseases (associated systemic diseases, high blood pressure, high cholesterol, 
and glaucoma) was not significantly different from patients recruited from PENN or 
JHU, except for cataracts (more patients had cataracts in MUST FS). Among the 182 
study participants, 23% had been diagnosed with associated systemic disease; 42% had 
high blood pressure; 36% had high cholesterol; 31% had glaucoma and 80% had 
cataracts. Their vision status can also be found in Table 3-2. 
 
Preferences Scores 
Estimates of treatment outcome importance using BWS are presented in Table 3-
3. We counted the total number of times across all surveys that each object (treatment 
outcome) was chosen as most worrying or least worrying, or was not chosen and 
computed the aggregate BWS score for each outcome. The number of counts was divided 
by the availability of each object (N=910, the number of times that an object appeared 
across 10 BWS tasks and 182 participants) to calculate a proportion. The aggregate BWS 
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score for glaucoma was the largest (387) and the score for cataracts was the smallest (-
333). Individual BWS scores for each outcome were calculated and the median and 
interquartile range of the scores (bounded by -5 and +5) and the standardized scores (0-
100) are also presented.  
 
Box plots of the standardized individual BWS scores and the VAS scores (on a 
scale from 0 to100) are shown in the Figure 3-1. According to the standardized 
individual BWS scores of the 6 outcomes, we identified that one group of outcomes, 
including vision not meeting the requirement for driving (median: 80), glaucoma 
(median: 70), and needing eye surgery (median: 60), were considered more worrying by 
study participants than the other group, including needing medicine for high blood 
pressure/cholesterol (median: 30), cataracts (median: 30), and infection (median: 20). 
Distributions of the scores of vision not meeting the requirement for driving and infection 
(e.g., sinusitis) had the largest variability as shown by interquartile ranges. 
  
With regard to the VAS scores, the median score of each outcome was 80 (vision 
not meeting the requirement for driving), 85 (glaucoma), 70 (needing eye surgery), 70 
(needing medicine for high blood pressure/cholesterol), 70 (cataracts), and 60 (infection) 
respectively. The ranking of the 6 outcomes by median of the standardized individual 
BWS scores was different from the ranking by median of the VAS scores. Comparing the 
distributions of medians of these 2 types of scores (see Figure 3-1), it suggests that using 
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BWS methods to elicit patient preferences seems easier to differentiate the importance of 
outcomes than using VAS methods. 
 
Associations between Patient Characteristics and Preferences Scores  
Table 3-4 shows the results from bivariate analyses that examined the 
associations between each patient characteristic and standardized individual BWS scores 
of the 6 outcomes. Bivariate analyses show that there were no significant differences in 
each score between the 2 populations (MUST FS vs PENN or JHU). For socio-
demographic variables, gender and age were not significantly associated with the scores 
of any outcome. Race (regression coefficient: 21.0; 95% CI: 11.6 – 30.4) and education 
(regression coefficient: 14.5; 95% CI: 4.6 – 24.5) were significantly (using 0.008 as 
statistical significance level) associated with BWS score of vision not meeting 
requirement for driving, and education (regression coefficient: -16.9; 95% CI: -26.4 – -
7.3) was significantly associated with the score of infection (e.g., sinusitis). Disease 
characteristics such as time since diagnosis and location of uveitis (anterior vs other) 
were not significantly associated with BWS scores of any outcome. Furthermore, when 
we compared the BWS scores between patients who had the respective outcome 
previously (cataracts, glaucoma, eye surgery, or high blood pressure/cholesterol) versus 
patients who did not, none of the associations reached the 0.008 level of significance. 
Table 3-5 shows the results of the 6 multiple linear regression models with each 
standardized individual BWS score as the dependent variables and in which we adjusted 
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for all characteristics simultaneously. The results were similar to those from the bivariate 
analyses and suggested that only race and education may influence patient preferences for 
treatment outcomes.  
 
DISCUSSION 
 We conducted a preference-elicitation survey of patients with non-infectious 
uveitis to measure the relative importance of treatment outcomes. Findings from BWS 
suggested that patients considered treatment outcomes including vision not meeting the 
requirement for driving, glaucoma, and needing eye surgery more worrying as compared 
against cataracts, needing medicine for controlling high blood pressure/cholesterol, or 
infection (e.g., sinusitis). 
 
 Our study provides useful information to decision makers, including patients, 
clinicians, and policy makers, about how patients themselves perceive the relative 
importance of outcomes that are crucial to making treatment decisions in non-infectious 
uveitis. Participants in our study generally considered ocular adverse events more 
worrying than systemic adverse events, except that cataracts were viewed the least 
worrying. Interestingly, based on the aggregate BWS scores, glaucoma was considered 
the most worrying by participants. Glaucoma and cataracts are both the common 
complications of uveitis and also side effects from corticosteroid therapy.[20] But 
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perhaps influenced by different disease prognoses and different abilities of the medical 
community to manage these diseases,[21, 22] our study participants had substantially 
different preferences for them. 
  
One important methodological issue in a preference-elicitation study is the 
question about in which patient population the preferences should be elicited and if 
patients’ prior experiences with treatments or outcomes affect the ratings.[23, 24] When 
designing the study, we chose to define broad inclusion criteria and enrolled 2 
populations in order to have the opportunity to explore patient characteristics. One 
population (MUST FS) included more severe cases of uveitis and those patients had long-
term experiences with treatments and outcomes. In the other population (PENN or JHU), 
most patients had less severe disease (anterior uveitis) and were less experienced with 
treatments or outcomes. We found, however, there were no significant differences 
between the 2 patient populations (MUST FS vs PENN or JHU). According to our 
regression analyses, the factors that influence preferences the most were socio-
demographic factors. For example, white patients in our study had significantly higher 
preference scores for vision not meeting the requirement for driving. Patients with higher 
educational levels had significantly higher preference scores for vision not meeting the 
requirement for driving but significantly lower preference scores for infection. For other 
variables examined, we did not detect any significant association between patients’ 
disease characteristics or prior experiences with outcomes and their preference scores. 
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The results remained similar even when we adjusted for all patient characteristic 
variables at the same time. 
  
   One of the challenges we encountered while designing the questionnaire was to 
ensure that participants had a common understanding of the treatment outcomes when 
they were doing preference-elicitation tasks. To achieve this goal, we asked participants 
to read the description of each outcome and complete the VAS tasks as a warm-up 
exercise before they completed the BWS tasks. Still, the variability of preferences 
between individuals was large. By examining the distribution of individual BWS scores, 
we found the interquartile ranges for the outcomes vision not meeting the requirement for 
driving and infection (e.g., sinusitis) were the largest. In the questionnaire, we associated 
vision with driving standard since vision is a rather abstract concept to describe. We 
found in our study white patients and patients with higher educational levels considered 
vision not meeting the requirement for driving more worrying than other patients. But we 
should be cautious about this finding since the association may be confounded by if and 
how frequent the participants drive, which we did not assess. We restricted the 
description of infection to sinusitis (most common one) since different kinds of infection 
can be perceived differently by patients. We found the preferences for infection still 
varied appreciably among participants. We were unsure if this reflected the actual 




As for comparing the results from VAS with BWS, we found the difference in the 
median of VAS scores for each outcome (ranged from 60 to 85) was smaller than the 
difference in the median of standardized individual BWS scores (20 to 80). One 
advantage of using BWS to elicit patient preferences is that it allowed us to ask 
participants in a way that they can make trade-offs between objects.[15] In contrast, in 
doing VAS tasks, there are no trade-offs involved so that method may be less sensitive to 
detect differences in the scores of the objects being rated.[25] In addition, the anchors 
(e.g., most or least serious outcome in our case) of VAS may have various meanings to 
individuals, which may affect our findings. We have demonstrated in this study that most 
participants can complete BWS tasks to indicate their preferences without major 
difficulty. Investigators who plan to elicit patient preferences may consider using this 
approach for their future studies. 
    
 Preference data such as what we collected are essential to benefit-harm 
assessment. As in our example, corticosteroid implant and systemic corticosteroids for 
non-infectious uveitis are associated with distinct systemic and ocular adverse events, so 
it is difficult to make decisions without doing a comprehensive benefit-harm assessment. 
Doing a quantitative benefit-harm assessment where multiple outcomes are involved 
inevitably requires assigning the relative importance to each outcome. With patient 
preference data, we are better informed of how patients, the most important stakeholder, 
make trade-offs between treatment benefits and harms. There is a growing interest in both 
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US Food and Drug Administration and European Medicines Agency in incorporating 
patients’ perspectives into their regulatory process, such as review of prescription drugs 
for marketing.[26] The current practice is somewhat limited to consulting patient groups 
or including patients on advisory committees but rarely uses such information 
quantitatively and explicitly.[13] Our study demonstrated an alternative and more explicit 
approach to incorporating the patients’ perspectives. We surveyed the key patient 
population who are most familiar with the condition and elicited their preferences for 
outcomes quantitatively. These data can be combined with clinical trial data to estimate 
the benefit-harm balance of competing treatments and provide an effective way to engage 
patients in the process of developing evidence that informs  preference-based decisions. 
   
 A number of limitations were identified in this study. We elicited the “stated 
preferences” from patients, in which patients completed preference-elicitation tasks based 
on their judgment of hypothetical descriptions of outcomes. Communicating with patients 
about treatment outcomes is a challenging task because the descriptions should include 
enough information to describe the outcome while not being too complicated for patients 
to understand. An individual participant’s familiarity with outcomes also may affect how 
these outcomes are perceived,[5] which is difficult to measure. In our study sample we 
included patients with anterior uveitis for whom either systemic or implant therapy may 
not be indicated; however, we did not observe significantly different preferences in 
patients with anterior uveitis from other patients. This, in fact, also assured us that our 
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findings were consistent across patient groups to some extent and the participants were 
not making choices randomly on BWS tasks. We hypothesized that patients’ experiences 
with outcomes may play a role in their preferences, but with our study sample size, we 
had limited power for testing for these hypotheses. Our study aim was to elicit 
preferences for patient-centered outcomes that are commonly seen in practice and 
measured in clinical studies. Thus, we developed our questionnaire using review of the 
existing literature and consultation with clinical experts. Another, probably better way to 
develop the questionnaire would be to conduct qualitative research with patients (e.g., 
focus group[27]) at the beginning. This would ensure that outcomes that are meaningful 
to patients are captured in the preference-elicitation tasks. 
 
 In summary, we have demonstrated a feasible approach to eliciting patient 
preferences for treatment outcomes. Participants in our study were comfortable and 
willing to complete BWS to indicate their preferences for outcomes. Patients with non-
infectious uveitis considered vision not meeting the requirement for driving, glaucoma, 
and needing eye surgery more worrying treatment outcomes as compared against 
cataracts, needing medicine for high blood pressure/cholesterol, or infection (e.g., 
sinusitis). Data on these patient preferences will provide important insights for patients 
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Table 3-4. Associations between patient characteristics and standardized individual best-worst scaling (BWS) scores of 









Table 3-5. Associations (adjusted) between patient characteristics and standardized individual best-worst scaling 
























Standardized individual BWS scores VAS scores
F A B C D E FA B C D E
3 636 2 1 31 2 3 4 4Ranking
 
Figure 3-1. Standardized individual best-worst scaling (BWS) scores, visual analogue scale (VAS) scores and rankings 
for the treatment outcomes.  
The box plots represent the median, interquartile range and 95% confidence interval for the scores of each outcome. Rankings are based 
on medians of the scores.  A = vision not meeting the requirement for driving; B = glaucoma; C = needing eye surgery; D = needing 
medicine for high blood pressure/cholesterol; E = cataracts; F = infection (e.g., sinusitis). 
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Additional analysis  
Table 3-6. Associations between patient characteristics and standardized individual best-worst scaling (BWS) scores of 
each treatment outcome (non-parametric test)
1 
  Standardized individual BWS scores of treatment outcomes 
 Vision not meeting 
the requirement for 
driving 
Cataracts Glaucoma Needing eye 
surgery 







MUST FS vs PENN or 
JHU 
0.022 0.410 0.386 0.363 0.771 0.960 








rho = -0.187) 
0.226 
(Spearman’s 
rho = 0.091) 
0.151 
(Spearman’s 
rho = -0.108) 
0.967 




rho = 0.059) 
Race (White vs Other) 0.0002 0.0032 0.970 0.439 0.775 0.0072 
Education (Some college 
or higher vs Grade 9 to 
12) 
0.016 0.612 0.228 0.972 0.324 0.0002 
Time since diagnosis 
(Spearman correlation) 
0.346 




rho = -0.126) 
0.300 
(Spearman’s 
rho = -0.078) 
0.946 
(Spearman’s 
rho = 0.005) 
0.254 




rho = 0.006) 
Location of uveitis 
(Anterior vs Other) 
0.015 0.657 0.248 0.430 0.554 0.659 
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Had cataracts (Yes vs No) - 0.084 - - - - 
Had glaucoma (Yes vs 
No) 
- - 0.144 - - - 
Had eye surgery (Yes vs 
No) 
- - - 0.911 - - 
Had high blood pressure 
or cholesterol (Yes vs No) 
- - - - 0.838 - 
1
We used Wilcoxon rank-sum test when the characteristics variable is categorical and calculated Spearman rank correlation 
when the characteristics variable is continuous. 
2
P-values < 0.008   
MUST FS = Multicenter Uveitis Steroid Treatment Trial Follow-up Study 
PENN = Sheie Eye Institute, University of Pennsylvania  












USING A PATIENT-CENTERED APPROACH TO BENEFIT-HARM 
ASSESSMENT IN TREATMENT DECISION-MAKING: A CASE 





 Interpreting findings from comparative effectiveness trials sometimes can be 
difficult since multiple treatment outcomes with different importance to patients are at 
play. The goal of this study was to demonstrate an approach to conducting quantitative 
benefit-harm assessment of competing treatments in which patient preferences are 
incorporated.  
Methods 
 We conducted a benefit-harm assessment using data from the Multicenter Uveitis 
Steroid Treatment Trial that compared corticosteroid implant versus systemic 
corticosteroids in treating non-infectious intermediate, posterior, and panuveitis. We 
focused on patient-centered treatment outcomes and incorporated measures of patient 
preferences that were derived from a recent survey into our estimation of the benefit-
harm balance over time. We also examined the joint occurrence of benefit and harm 
outcomes in the trial participants. 
Results 
 Benefit-harm metrics were calculated for each time point that summarized the 
numbers of cases with each outcome, caused or prevented by the implant therapy 
compared with systemic therapy if 1000 patients were treated. The benefit-harm metric 
was -129 (95% CI: -242 to -14), -317 (-436 to -196), -390 (-514 to -264) and -526 (-687 
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to -368) and the probability of the metric being positive was 1%, 0%, 0%, and 0% at 6, 
12, 18, and 24 months follow-up, respectively, which implies that implant therapy has a 
worse benefit-harm balance than systemic therapy. Our interpretation of the benefit-harm 
balance remained similar in the analyses when we varied the weights assigned to 
outcomes and when we considered the joint occurrence of benefits and harms. 
Conclusions 
 We demonstrated a quantitative approach to benefit-harm assessment that is 
focused on patient-centered outcomes and that incorporates patient preferences. The 
approach estimates the benefit-harm balance between competing treatments and can be 




 Randomized comparative effectiveness trials are used to make head-to-head 
comparisons between competing treatments and generate evidence on treatment 
effectiveness and safety.[1] For example, the Multicenter Uveitis Steroid Treatment 
(MUST) Trial was designed to compare two active treatments that both work in treating 
non-infectious intermediate, posterior, and panuveitis.[2] Eligible patients were 
randomized to either fluocinolone acetonide implant (implant therapy) or systemic 
corticosteroids plus immunosuppression when indicated (systemic therapy) and followed 
for 24 months. Although no significant difference in visual acuity change from baseline 
was detected between the two treatment groups, implant therapy was associated with 
more ocular adverse effects (e.g., cataracts and glaucoma) while systemic therapy was 
associated with more systemic adverse effects (e.g., hypertension and infections).[3] 
 
 Interpreting findings from such a comparative effectiveness trial is difficult for 
most patients, clinicians, or policy makers. It often remains uncertain if one treatment is 
superior to the other because multiple benefit and harm outcomes are at play. A number 
of quantitative approaches for benefit-harm assessment exist that deal with such 
multidimensional tasks and have the potential to substantially aid our interpretation and 
judgment of comparative treatment effectiveness.[4, 5] Quantitative benefit-harm 
assessments can consider multiple outcomes and patient characteristics to provide a 
single metric, if desired, that reflects the benefit-harm balance. Since patients may 
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perceive the importance of each benefit or harm outcome differently, these summary 
metrics of benefits and harms also allow for taking into account the patient preferences 
for treatment outcomes.[5] 
    
 Joint occurrence of benefit and harm outcomes is another important, though 
usually neglected, issue to consider when doing quantitative benefit-harm assessment.[5-
9] Occurrence of outcomes can be correlated rather than independent if, for instance, they 
typically co-occur with each other within patients. Nonetheless, treatment effects on each 
outcome are traditionally reported separately in the medical literature.[5, 10] Some 
approaches to benefit-harm assessment that account for such joint occurrence of 
outcomes have been developed, yet are not commonly applied.[11-15] 
  
The objective of the present study was to demonstrate a patient-centered approach 
to benefit-harm assessment that specifically incorporates patient preferences. We used the 
example of the MUST Trial that compared implant therapy with systemic therapy in 
patients with intermediate, posterior and panuveitis. With patient-level data from the trial, 
we also examined the joint occurrence of benefit and harm outcomes in these patients. 
 
 




Data Source: The MUST Trial 
 The MUST Trial is a randomized comparative effectiveness trial designed to 
compare corticosteroid implant versus systemic corticosteroids in patients with non-
infectious intermediate, posterior and panuveitis. Details on the study design and primary 
results of the trial were reported previously.[2, 3] In brief, patients aged 13 or older who 
had uveitis in at least one eye and who were indicated for systemic corticosteroids were 
randomized to implant or systemic therapy. Patients in the implant therapy group 
received in the eligible eye a surgical fluocinolone acetonide implant (0.59 mg) that 
delivers corticosteroids intravitreally. Patients in the systemic therapy group were treated 
with oral corticosteroids (prednisone) supplemented with immunosuppressive agents 
according to treatment guidelines.[2, 16] Participants were recruited from 23 clinical 
centers across the United States, the United Kingdom, and Australia from December 
2005 to December 2008 and were followed for at least 24 months. All participants 
provided their informed consent and the institutional review boards at the clinical centers 
and resource centers approved the study. 
 
Outcomes Included for Benefit-Harm Assessment 
Our aim was to do a patient-centered benefit-harm assessment, so we focused on 
patient-centered outcomes (as opposed to biomarkers or other surrogate outcomes) 
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measured in the MUST Trial that are deemed important to decision-making. The goal of 
treating these patients is to preserve their vision from getting worse and, at the same time, 
to minimize adverse effects caused by the treatments. For the vision outcome, we 
examined the proportion of patients who did not respond to treatment at each time point, 
which was defined as their best-corrected visual acuity in the better-seeing eye staying at 
or even decreasing to worse than 20/40 (vision not meeting the requirement for driving). 
For ocular and systemic adverse effects of treatments, we examined at each time point the 
proportion of patients who had the following outcomes: incident cataracts, incident 
glaucoma, requiring cataract surgery, requiring intraocular pressure-lowering surgery 
(glaucoma surgery), prescription-requiring hypertension, prescription-requiring 
hyperlipidemia, and prescription-requiring infections. The time frames of our assessment 
of these outcomes were 6, 12, 18, and 24 months after randomization. The unit of the 
analysis was the individual patient. 
 
Relative Importance for Outcomes 
 In a benefit-harm assessment to compare multiple outcomes on a single metric, 
we needed to assign weights to outcomes based on their relative importance. Therefore, 
in our analysis we assigned the weights using data from a recent survey that elicited 
patient preferences for treatment outcomes in non-infectious uveitis.[17] Briefly, the 
survey asked 182 patients with non-infectious uveitis to complete the “best-worst 
scaling” exercise, a preference-elicitation method used in health economics where 
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patients have the tasks to repeatedly select the most and the least worrying from a list of 
outcomes (in the survey 3 outcomes per task). Among all outcomes being compared, 
vision not meeting the requirement for driving, incident glaucoma, requiring cataract 
surgery and requiring glaucoma surgery were thought to be more worrying by 
respondents as compared against incident cataracts, prescription-requiring hypertension, 
prescription-requiring hyperlipidemia, or prescription-requiring infections. Estimates of 
patient preferences for these outcomes were incorporated into our benefit-harm 
assessment.   
 
Benefit-Harm Metric 
We summarized the treatment effects on different outcomes (weighted by each 
outcome’s relative importance) in a “benefit-harm metric” that reflects the benefit-harm 
balance. First, based on the MUST Trial data, we calculated the numbers of cases with 
respective outcome (outcome x) if 1000 patients were treated with implant therapy 
(NX,IMP) or systemic therapy (NX,SYS). Second, we calculated the cases prevented or 
caused if 1000 patients were treated with implant therapy as compared against systemic 
therapy (Nx = NX,SYS - NX,IMP). A positive number represents the number of cases 
prevented and a negative number represents the number of cases caused by implant 
therapy. Third, we assigned weights (WX, relative importance) to these outcomes 
according to the preference measures elicited in the patient preferences survey. We then 
computed a benefit-harm metric that summarizes the overall numbers caused or 
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prevented by implant therapy and that incorporates the relative importance of outcomes. 
If the benefit-harm metric is positive, it suggests that implant therapy is superior to 
systemic therapy since the implant therapy prevented more cases overall. 
  
We computed the benefit-harm metrics at 6, 12, 18, and 24 months after 
randomization. In addition, we varied the weights assigned to outcomes as sensitivity 
analyses to evaluate whether our study conclusions would change with regards to 
different assigned weights. We used bootstrapping approach to incorporate the statistical 
uncertainty. Bootstrapping was conducted by drawing a random sample from the 
observations in each treatment group and calculating the benefit-harm metric 10000 
times. Thereby, we obtained 10000 replicates of the metric to compute its 95% 
confidence interval (CI) and the probability that the metric is positive. Analyses were 
performed using Stata 11.2 (StataCorp LP, Colllege Station, TX) and R statistical 
software 3.0.1. 
 
Joint Occurrence of Benefits and Harms  
To examine the joint occurrence of benefit and harm outcomes in patients in the 
MUST Trial, we defined two benefit categories (based on patients’ vision outcome) and 
three harm categories (based on their experiences with adverse effects). The “benefit 
categories” were: (1) patients’ visual acuity of the better-seeing eye stayed at or improved 
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to 20/40 or better (“With benefits”); (2) patients’ visual acuity of the better-seeing eye 
stayed at or decreased to worse than 20/40 (“No benefits”). The “harm categories” were 
defined as: (1) patients had no adverse events of interest (“No harms”); (2) patients only 
had the adverse events that are less worrying (according to the preference survey 
abovementioned) including incident cataracts, prescription-requiring hypertension, 
prescription-requiring hyperlipidemia, or prescription-requiring infections (“Minor 
harms”); (3) patients had any of the adverse events that are more worrying including 
incident glaucoma, requiring cataract surgery and requiring glaucoma surgery (“Moderate 
harms”). Finally, we created “benefit-harm categories” that consider benefits and harms 
jointly: two benefit categories x three harm categories, e.g., “With benefits/No harms”, 
“With benefits/Minor harms”, “With benefits/Moderate harms”, and so on. One more 
category (“Missing data”) was created that included patients with missing data of their 
visual acuity. These patients were died or loss to follow-up, or their visual acuity was not 
or could not be measured (see Table 4-1 for different benefit-harm categories). 
      
We then assigned every patient in the MUST Trial to each of the seven benefit-
harm categories based on their experiences with benefit and harm outcomes during 
follow-up. We compared the distributions between the two treatment groups at each time 
point. We also did stratified analysis by baseline vision (visual acuity of the better-seeing 
eye 20/40 or better, or worse than 20/40 at baseline) and we examined the distribution of 




 Table 4-2 shows the data input for the benefit-harm assessment, the proportion of 
patients in the MUST trial who ever had each outcome during follow-up (by treatment 
group) and the weights (i.e., reflecting patient preferences) assigned in the main and 
sensitivity analyses. Patients’ outcomes at four different time points are presented: 6, 12, 
18, and 24 months after randomization. At baseline, 82% (210/255) of patients had 
cataracts and 3% (6/237; 18 patients with missing data) had glaucoma, so these patients 
were considered not at risk when quantifying incident cataracts or incident glaucoma. In 
the main analysis, the weights assigned were based on the preference measures obtained 
in the preference-elicitation survey. We varied the weights in the first sensitivity analysis 
by assigning 1.0 to more worrying outcomes and 0.5 to less worrying outcomes. In 
sensitivity analysis two, we assigned 1.0 to the visual acuity outcome (as this is the 
primary outcome in the trial) and 0.5 to other more worrying outcomes and 0.25 to less 
worrying outcomes. 
  
 An example of calculation of the benefit-harm metric (main analysis, 24 months 
follow-up) is provided in Table 4-3. We calculated the numbers of cases with respective 
outcome if 1000 patients were treated with implant or systemic therapy and then the 
numbers of cases with respective outcome caused or prevented by implant therapy. We 
assumed at baseline 82% of patients had already had cataracts and 3% of patients had had 
glaucoma (based on data from the MUST Trial). Take the incident glaucoma outcome as 
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an example. Our calculations show that there would be 226 and 60 cases with incident 
glaucoma if 1000 patients were treated with implant and systemic therapy, respectively. 
Thus, 166 cases with incident glaucoma would be in excess comparing implant therapy 
with systemic therapy. The numbers caused or prevented by implant therapy were then 
multiplied by the weights, and were summed to compute the benefit-harm metric. 
  
Results of the main and sensitivity analyses of the benefit-harm metric at each 
time point are shown in Table 4-4. In the main analysis, the benefit-harm metric is -129, 
-317, -390 and -526 at 6, 12, 18, and 24 months follow-up, respectively, implying that 
implant therapy has a worse benefit-harm balance than systemic therapy. The 95% CIs 
and the probability that the metric is positive, meaning that implant therapy would be 
superior to systemic therapy, is 1%, 0%, 0%, and 0%, respectively. Results of the 
sensitivity analyses are similar. The benefit-harm metrics are more and more distant from 
0 (negative) across the 6, 12, 18, and 24 months follow-up, and the probabilities of the 
index being positive are all small or 0%. This suggests that systemic therapy may be 
superior to implant therapy given the outcomes and time frames defined in our 
assessment. 
 
Table 4-5 shows the patients’ outcomes at 24 months follow-up by accounting for 
the joint occurrence of benefits and harms. At 24 months follow-up, 66% of patients in 
implant group versus 71% in systemic group were in the “With benefits” category. 
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Combined with their experience with harms, most patients (49%) in the implant group 
were assigned to the “With benefits/Moderate harms” category, while only 23% in 
systemic group were in this category. 
  
Results stratified by baseline vision are also shown in Table 4-5. Most patients 
started with vision 20/40 or better of their better eye managed to maintain their vision 
(82% in both treatment groups) at 24 months follow-up. On the other hand, among 
patients started with vision worse than 20/40 of their better eye, 36% of patients in 
implant group versus 43% in systemic group got improved in their vision to 20/40 or 
better. Generally speaking, regardless of the benefit category they were assigned to, 
patients in the implant group were more likely to have moderate harms and patients in 
systemic group were more likely to have no harms or minor harms. We also plotted the 
distribution of patients to assigned benefit-harm categories by treatment group over time 
in the Figure 4-1. 
 
DISCUSSION 
 Based on a randomized comparative effectiveness trial, we quantitatively assessed 
the benefits and harms of corticosteroid implant versus systemic corticosteroids in 
patients with non-infectious intermediate, posterior, and panuveitis. We adopted a 
patient-centered approach in our assessment where we focused on patient-centered 
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outcomes and assigned weights (patient preferences for these outcomes indicating their 
relative importance) to each outcome according to a preference-elicitation survey of 
patients. Given the outcomes and time frames we defined, the results showed that 
systemic therapy may be superior to implant therapy. 
 
 Using a quantitative approach to benefit-harm assessment, as we did in this study 
may provide more clarity and transparency than using a qualitative approach, in 
particular of the decision-making being challenging due to many different outcomes. In a 
quantitative benefit-harm assessment, a common metric is often needed to summarize and 
compare the treatment effects for both benefits and harms.[5] Treatment effects in 
clinical trial reports are commonly expressed as relative risks (e.g., risk ratio, odds ratio, 
or hazard ratio). But because the same relative risk can translate into considerably 
different effects for different patients as the respective absolute risks are different, it 
seems necessary to use absolute risks to put multiple outcomes on the same metric.[4] 
For example, a relative risk of 0.5 (50% risk reduction) for heart attack can mean that 
25% (absolute risk of the control group: 50%) or 1% (absolute risk of the control group: 
2%) of the events are prevented. It is thus probably not sensible if we rely on relative 
risks alone to do a quantitative benefit-harm assessment. 
  
In our analysis, we created a common metric (number of cases with the outcome 
if 1000 patients were treated) and put all outcomes on the same metric based on the 
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absolute risks (probabilities). We calculated the numbers of cases with the outcome that 
would be caused or prevented by the implant therapy compared with systemic therapy, 
and then properly assigned weights to these numbers to generate the benefit-harm metric. 
Based on the metric, we were able to tell which treatment would be superior to the other 
considering both benefit and harm outcomes. We used bootstrapping methods to calculate 
the 95% CI of the metric and the probability of the metric being positive, which informed 
us of the statistical uncertainty around the benefit-harm balance. Our quantitative 
approach to benefit-harm assessment was transparent in that the specific outcomes 
considered, weights assigned, and the uncertainty of the data were clearly laid out. This is 
in contrast to using a qualitative approach in which the outcomes and weights used and 
the assumptions and judgment made at every step of a benefit-harm assessment are often 
less clear or transparent to readers. 
 
 Our study also demonstrated how the joint occurrence of benefits and harms can 
be examined when doing benefit-harm assessment. In clinical trials, the evaluation of 
treatment effect is usually done separately for each outcome.[10] However, it would be of 
great interest to patients and clinicians if data of the joint impacts of benefit and harm 
outcomes on the same individual are available.[10] For example, we computed and 
plotted the distribution of benefit-harm categories (in which the joint probability of the 
occurrence of benefits and harms were examined, see the Figure 4-1) by treatment group. 
We found that the distribution of outcomes was somewhat different in the implant and 
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systemic groups. At 24 months follow-up the distribution of the harm categories was not 
the same between the two treatment groups, although the proportions of patients who 
were assigned to “With benefits” category were similar (66% vs 71%). Most patients in 
the implant group had moderate harms, but patients in the systemic group were more 
evenly distributed among no, minor, and moderate harms. Such information on the joint 
occurrence of benefits and harms is not commonly reported in the current literature of 
clinical trials, but would be extremely helpful when patients and clinicians desire to make 
personalized treatment decisions. 
 
 Assigning weights (relative importance) to outcomes is no doubt the most 
controversial part of a benefit-harm assessment and is inevitably subjective. Nevertheless, 
it remains essential, as in clinical practice, because it is not sensible if all outcomes were 
considered to be of equal importance. Even if one chooses to use a qualitative approach 
instead, weighting is still implicitly conducted as some outcomes would be viewed more 
important than others; thus, the results are sensitive to these “implicit weights”.[6] The 
weighting of outcomes in our benefit-harm assessment were done from a population 
perspective, where we used preference data elicited from a patient population. We 
decided up front to conduct a preference-elicitation survey of patients with non-infectious 
uveitis to help us choose appropriate weights for each outcome. We were comfortable 
with using the findings from the survey to determine the weights since we found in the 
survey that the preference estimates were consistent across different patient groups.[17] 
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However, the variability of the preference estimates were also found to be rather large 
between individuals.[17] The advantage of using a quantitative approach to benefit-harm 
assessment is its transparency and reproducibility. The analyis can easily be repeated and 
modified if anyone disagrees with the outcomes included or the weights assigned to 
outcomes. Hence, instead of using weights derived from a population, different weights 
can be assigned depending on each individual’s preferences. In addition, a reproducible 
approach to benefit-harm assessment greatly facilitates sensitivity analyses, which are 
essential to assess how much the benefit-harm balance changes if different data inputs are 
chosen. 
  
Selection of outcomes for benefit-harm assessments is a critical step. One may see 
it as a limitation that we did not consider "control of inflammation" in our benefit-harm 
assessment. The fluocinolone acetonide implant to treat non-infectious uveitis was 
approved by the FDA based on its effect on control of inflammation (rate of recurrence of 
uveitis) [18, 19], and the goal of the treatment is to control the inflammation in the eye 
with the hope of preserving patient’s vision. Since our benefit-harm assessment directly 
considered visual acuity as the outcome of primary interest rather than using a marker of 
inflammation as a surrogate, we saw little reason to include control of inflammation in 
the analysis. This may, however, neglect some potential benefits provided by the implant 
as implant therapy was shown to be more effective in reducing uveitis activity.[3] 
Whether this treatment effect on controlling intraocular inflammation can be translated 
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into the treatment effect on patient’s vision would require further investigation in long-
term randomized studies. 
 
It is also interesting to note that our results are somewhat contradictory to the 
findings of health-related quality of life and health utility. For example at 24 months 
follow-up, the change from baseline of the EQ-5D health utility index was larger in 
implant group versus systemic group (treatment effect = 0.04, p-value = 0.06)[3]. The 
EQ-5D instrument assesses several generic health dimensions including mobility, self-
care, usual activities, pain/discomfort and anxiety/depression.[20] Such an instrument is 
designed to be generalizable across various conditions and treatments and often used to 
compute quality-adjusted life years in cost-effectiveness studies as a way to capture the 
overall treatment effect on patients’ health.[21] Although we have demonstrated that 
patients do make trade-offs between different treatment outcomes, it is likely that the 
impact of some outcomes on patients may not be large enough to affect their overall 
health status, or that the instruments measuring their health status are not sensitive 
enough in the specific disease of interest.[22] However, our approach is more specific to 
the decision-making context and we clearly defined the outcomes for benefit-harm 
assessment. Thus, we may capture the aspects of benefits and harms that are perhaps 




Some limitations of this study were identified. In our decision making context, we 
only focused on patient-centered outcomes that are common in patients with non-
infectious uveitis. Some harm outcomes of implant or systemic therapy (e.g., 
endophthalmitis or psychiatric disorder), though much less common, may also be of 
importance when making treatment decisions for individuals. The study time frame is 24 
months after randomization, the same time points at which the primary outcome was 
measured. Therefore, our model was not able to capture the potential systemic 
complications that may occur years later after treatment. To study harms that are rare and 
long-term, randomized trials are not the most efficient design and it requires data from 
observational studies or surveillance. Future methodological research is needed to 
address the question of how data from observational studies or surveillance can be 
incorporated into a benefit-harm assessment. Finally, when generating the benefit-harm 
categories and computing the benefit-harm metrics, we categorized visual acuity outcome 
and combined different harm outcomes together. This can lead to much information loss 
but it is inevitable in any benefit-harm assessment to reduce some of the multi-
dimensionality in order to arrive at estimates of the benefit-harm balance that facilitates 
treatment decision-making. 
 
   In summary, we conducted a quantitative benefit-harm assessment of implant 
versus systemic therapy in patients with non-infectious intermediate, posterior, and 
panuveitis to help us make treatment decisions. We have demonstrated how we selected 
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the outcomes, considered the joint occurrence of benefits and harms and incorporated the 
patient preferences for outcomes in the analysis. In line with the recent interest in patient-
centered outcomes research,[23, 24] we believe our approach is useful and deserves 
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Table 4-1. Benefit-harm categories 
 
No harms 
Patients had no adverse 
events of interest 
Minor harms 
Patients only had the adverse 
events that are less worrying 
including incident cataracts, 
prescription-requiring 
hypertension, prescription-
requiring hyperlipidemia, or 
prescription-requiring 
infections 
Moderate harms  
Patients had any of the adverse 
events that are more worrying 
including incident glaucoma, 
requiring cataract surgery and 
requiring glaucoma surgery 
With benefits 
Patients’ visual acuity of 
the better-seeing eye 
stayed at or improved to 
20/40 or better 
(1) With benefits/No 
harms 
(2) With benefits/Minor 
harms 
(3) With benefits/Moderate 
harms 
No benefits 
Patients’ visual acuity of 
the better-seeing eye 
stayed at or decreased to 
worse than 20/40 
(4) No benefits/No harms (5) No benefits/Minor harms 
(6) No benefits/Moderate 
harms 
















Table 4-4. Main and sensitivity analyses of benefit-harm metrics at different time 










6 months -129 -242 to -14 1% 
12 months -317 -436 to -196 0% 
18 months -390 -514 to -264 0% 
24 months -526 -687 to -368 0% 
Sensitivity analysis one 
6 months -201 -362 to -39 1% 
12 months -482 -665 to -298 0% 
18 months -603 -800 to -412 0% 
24 months -808 -1049 to -570 0% 
Sensitivity analysis two
 
6 months -115 -245 to 13 4% 
12 months -292 -421 to -161 0% 
18 months -339 -467 to -209 0% 
24 months -439 -588 to -294 0% 
*95% confidence interval and the probability of the metric being positive were calculated based 
on the 10000 bootstrapping replicates.  
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Table 4-5. Number of patients assigned to each benefit-harm category
1





Implant            Systemic                  Implant           Systemic
6 months 12 months 
Implant            Systemic                  Implant             Systemic
18 months 24 months 
 
Figure 4-1. Distribution of patients to assigned benefit-harm categories over time by 
treatment group.  
For implant group (n=129) and systemic group (n=126), we categorized the patients first into 
“With benefits” or “No benefits” and further sub-categorized them into “No harms”, “Minor 
harms” or “Moderate harms”. The definition of benefit and harm categories can be found in the 


















Summary of findings 
  
The goal of treatments is to provide benefits to patients, but they may come with 
harms. If multiple benefit and harm outcomes are associated with the treatments, it 
becomes more challenging to make treatment decisions.[1] Doing a comprehensive 
benefit-harm assessment is thus helpful, even necessary, for different stakeholders, 
including patients, clinicians, or policy-makers to select the most appropriate treatments. 
In this dissertation, we conducted a quantitative and patient-centered benefit-harm 
assessment of corticosteroid implant versus systemic corticosteroids in intermediate, 
posterior, and panuveitis. Several methodological issues of benefit-harm assessments 
have also been examined. 
 
Selection of outcomes 
 
 Defining the decision-making context is the first and important step of doing a 
benefit-harm assessment, which involves specifying the population(s), intervention(s), 
comparison(s), outcome(s), and time frame(s). We emphasize that we should select 
patient-centered outcomes because this will help generate results that are relevant to 
patients. Nonetheless, investigators are often challenged by the fact that surrogate 
outcomes are commonly used in clinical trials to demonstrate treatment effects, instead of 
patient-centered outcomes.[2] In chapter 2, we did a survey of drugs approved by the 
United States Food and Drug Administration (FDA) to learn how the drug reviewers 
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dealt with surrogate outcomes when they were assessing the benefits and harms of a drug. 
We went through the medical review documents of included drug approvals to examine 
how they considered the evidence of surrogacy. Specifically, we examined if they 
considered how treatment effects on surrogate outcomes predict treatment effects on 
patient-centered outcomes. 
  
 We were surprised of our findings that the way the FDA dealt with surrogate 
outcomes was not consistent across disease areas and, that in some diseases, evidence of 
surrogacy was seldom discussed in the medical reviews. For example in glaucoma, most 
drugs were only approved based on surrogate outcomes (intraocular pressure), and the 
rationale for using surrogates was not clearly stated.[3] On the contrary, in diseases such 
as osteoporosis, FDA required evidence on patient-centered outcomes (fractures) for drug 
approval.[4] We accordingly proposed a framework for selecting outcomes in a benefit-
harm assessment. We emphasize the importance of using patient-centered outcomes 
when doing a benefit-harm assessment if these outcomes are available. If data on such 
outcomes are not available to us, we should critically examine the evidence of surrogacy. 
For example in diabetes, a systematic review of the evidence on how treatment effects on 
lowering blood sugar levels can predict treatment effects on micro- or macro-vascular 
events would be extremely helpful.[5] Moreover, we should carefully consider if the 





Role of patient preferences 
 
 Another key element in a benefit-harm assessment is the relative importance of 
outcomes. To conduct a quantitative benefit-harm assessment in which multiple 
outcomes are compared against each other, one must properly assign weights to these 
outcomes in order to reflect their relative importance when estimating the benefit-harm 
balance.[6] In chapter 3, we conducted a survey of patients with uveitis to elicit the 
relative importance (preferences) of treatment outcomes. We used best-worst scaling 
(BWS) approach, which is getting more and more popular in health care research,[7] to 
elicit participants’ preferences for the six outcomes that are meaningful to decision-
making. In the questionnaire, participants were first asked to read the description of each 
outcome and complete visual analog scale (VAS) tasks to indicate how serious they 
perceive the outcomes to be (as a warm-up exercise). Then, they were asked to do the 
BWS tasks.  In each BWS task they made trade-offs between outcomes by indicating the 
most and least worrying out of three outcomes. Our main findings showed that patients 
with uveitis considered vision impairment, glaucoma, and need for eye surgery more 
worrying as compared against cataracts, needing medicine for high blood 
pressure/cholesterol, or infections. 
  
 In our survey, we included two populations of patients with uveitis. One 
population consisted of patients who were more severe and who had been diagnosed for a 
longer time period and the other consisted of patients who were less severe and who had 
152 
 
less experiences with the disease. Interestingly, preference results of BWS were not 
significantly different between these two populations. Furthermore, in regression 
analyses, we only identified demographic characteristics such as race and educational 
level to be the factors that may influence their preferences, while other disease 
characteristics or their prior experiences with outcomes were not significantly associated 
with the preferences. Another interesting methodological finding of our survey is from 
comparing the results of BWS versus VAS. We found using BWS approach to elicit 
patient preferences, a more differentiated distribution of relative importance of outcomes 
was obtained than using VAS approach. This suggests that using BWS approach seems to 
be easier than using VAS approach to differentiate the relative importance of outcomes. 
The preference data we collected provided a basis for assigning weights in our later 
benefit-harm assessment. 
 
A quantitative benefit-harm assessment based on a comparative effectiveness trial 
  
 Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial[8] showed 
that both corticosteroid implant and systemic corticosteroids work to preserve patient’s 
vision, but it also indicated that these therapies are associated with distinct systemic and 
ocular adverse effects. We conducted a benefit-harm assessment of these two treatment 
strategies in patients with intermediate, posterior, and panuveitis in chapter 4. We 
selected the patient-centered outcomes for benefit-harm assessment according to our 
framework mentioned above. To compare multiple outcomes against each other, we 
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generated a common comparison metric. We used absolute risk data of the MUST Trial 
to compute the number of cases prevented or caused by implant therapy as compared to 
systemic therapy if 1000 patients were treated, and assigned weights to these outcomes 
(based on our findings of the patient preference survey) to compute the benefit-harm 
metrics. If the benefit-harm metric was positive, it indicated that implant therapy had a 
better benefit-harm balance than systemic therapy.  
 
 We also examined the joint occurrence of benefit and harm outcomes in the trial 
participants. Oftentimes, results of each outcome in a clinical trial are reported 
independently in the literature.[9] But readers have no clues to if the benefit and harm 
outcomes co-occur in the same group of patients or not. By accounting for the joint 
occurrence of benefits and harms, we were able to assess their joint impacts on the same 
patient. We also calculated the benefit-harm metrics at different time points after 
randomization (up to two years) to learn  how the benefit-harm balance would change 
across time. In addition, we did sensitivity analyses where we assigned different weights 
to outcomes to evaluate if and how our conclusions may vary. We found the results were 
consistent across different scenarios and all analyses suggested that systemic therapy may 







Limitations and implications for future research 
 
 Here we discuss the limitations of the dissertation and the implications for future 
research. 
  
 In this dissertation, we developed a framework for selecting outcomes in benefit-
harm assessments. We emphasize the importance of using patient-centered outcomes 
whenever possible, but if using surrogate outcomes is inevitable, we should carefully 
examine the evidence for surrogacy. However, our proposed framework may be limited 
by that there are insufficient prior studies that have evaluated the validity of surrogate 
outcomes. The highest level of evidence for surrogacy requires to have randomized 
clinical trials showing treatment effects on surrogate outcomes predict treatment effects 
on patient-centered outcomes.[10] Doing such randomized clinical trials with patient-
centered outcomes as the primary outcome often needs large sample size and long 
follow-up time. Limited funding and resources to support a large and long-term study, 
and lack of interest from industry where most of these drug trials are done would pose 
real challenges here.[11] 
 
 Another issue is that even with good evidence for surrogacy, to make judgments 
on the generalizability of the evidence can be difficult.[12] For example, there were some 
large and long-term trials conducted to examine if the treatment effects on lowering 
blood sugar levels can predict treatment effects on some micro-vascular events.[13, 14] 
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With this evidence, can we apply it to different drugs in the same class? Probably yes. 
Can we apply this evidence to the drugs in different classes? Probably not sure since 
drugs in another class can have an effect on patient-centered outcomes through other 
causal pathways, and this effect may not be captured by the surrogate outcomes.[15] In 
the future, we can initiated more large-scale systematic reviews and/or meta-analysis to 
examine the evidence for surrogacy by different drugs/drug classes. This will allow us to 
study for what drugs we are more confident in using surrogate outcomes for benefit-harm 
assessment, and for what drugs there may be knowledge gaps in the evidence for 
surrogacy. Thus we can focus on these evidence gaps and design studies that address the 
issue. 
    
 Different stakeholders may have different views of the relative importance of 
outcomes.[16] In our benefit-harm assessment, we decided to adopt a patient-centered 
approach and incorporated patient preferences in our analysis. At first, we were 
concerned that patients who had been diagnosed with uveitis for a longer time period may 
have different preferences as compared to patients who are less experienced with the 
disease. Some people thought that we should focus on the preferences from patients who 
are recently diagnosed because their preferences reflect those patients who are in the 
position to make a treatment decision. However, it was challenging to recruit such 
patients since it required a large number of clinics to contribute to our study. On the 
contrary, some people argued that it is probably also necessary to include patients who 
have more experiences with the disease and treatments because they may be more 
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familiar with treatment outcomes. Our findings showed that the influences of disease 
characteristics or their experience with outcomes on preferences, in fact, were limited. 
Instead, demographic characteristics such as race and education could influence their 
preferences. The associations we observed were based on our study sample and may not 
be generalizable to other populations or diseases. Survey of a larger population of 
patients can be conducted in the future to further examine this issue. 
  
 One drawback of this dissertation is that we did not do our benefit-harm 
assessment prospectively. We, the same as most investigators who plan to do benefit-
harm assessments, mainly rely on existing data and our studies are limited by what 
outcome data have been collected in clinical trials. Most outcome data collected in trials 
are of interest to clinicians but may not be so to patients. A more ideal way can be, before 
the trials are initiated, to conduct qualitative studies such as focus groups[17] with 
relevant patient populations to learn what outcomes are deemed important by patients, 
and then to elicit the preferences for such outcomes. Not only will this information be 
useful to those conducting benefit-harm assessments, but also it will be informative to 
clinical trialists for planning the trial and deciding on what outcome data they need to 
collect. Before the trial starts, investigators who are doing benefit-harm assessment can 
pre-specify the outcomes that will be included and pre-specify the weights that are 
assigned to each outcome in the analysis. This prospective approach can ensure that we 
don’t miss out the outcomes that are important to patients’ decision-making and also 
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minimize the bias that may be introduced should the benefit-harm assessment be done 
post hoc. 
 
  The issue of defining outcomes for benefit-harm assessment becomes even more 
important given the preference-elicitation approach we chose for this dissertation. We 
adopted the BWS approach to assess patient preferences, where we asked participants to 
make trade-offs among the six outcomes that are meaningful to decision-making. If we 
included more (or less) outcomes, the preferences results would probably be different, 
because participants would instead make trade-offs among different sets of outcomes. 
Also, the benefit and harm outcomes included in our assessment were mainly clinical 
outcomes. We did not include other important elements such as the burden of the 
treatments and the cost to patients as we wanted to focus on clinical outcomes first. For 
patients with uveitis to choose between corticosteroid implant and systemic 
corticosteroids, these two elements may also be essential to their decision-making 
because one treatment requires additional surgery of the implant and the other treatment 
requires long-term use of medications, which incurred distinct burden and cost to 
patients.[18] Our study only considered clinical outcomes but in the future, we can try 
adding the other two dimensions into the benefit-harm assessment. It is challenging to do 
but for sure deserves further study. 
  
 Assigning relative importance (weights) to different outcomes is one of the 
controversial parts of a benefit-harm assessment, because this exercise is by nature 
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subjective.[19] We did a preference survey of patients with the condition to figure out 
what the relative importance is for each outcome, but we still find it challenging to 
transfer these numbers into weights when doing the analysis and to properly 
communicate with stakeholders about this exercise. Nonetheless, we believe that to do a 
benefit-harm assessment that is transparent and replicable, documenting the weights used 
is of great importance and necessary.[20] To overcome this issue, we emphasize the 
importance of doing multiple sensitivity analyses with different weights assigned to learn 
if and how the study results would vary. 
 
 Our benefit-harm assessment was done from a population perspective. We used 
preference data from a group of patients with the condition and clinical outcome data of a 
randomized controlled trial. Thus, we should acknowledge that we are assessing the 
overall benefit and harms for a population when interpreting our findings. If one wants to 
apply this evidence to treat an individual, individual patient preferences and their 
characteristics should thus be considered. Also, the results would be a probabilistic 
estimate of the treatment being more beneficial than harmful given certain patient 
characteristics and preferences and would seldom be a yes/no answer. To conduct 
benefit-harm assessment that is more personalized, we may need to design more large-
scale clinical trials (with a more heterogeneous patient group) or conduct modeling 
studies for benefit-harm assessments under different scenarios.[21] This will help us 




 In this dissertation, we examined the health outcomes, factored in the patient 
preference estimates, and generated a “benefit-harm metric” as a way to summarize the 
impacts of treatments on patient’s health and used it for treatment comparison. An 
interesting topic for further research may be to see how our approach to benefit-harm 
assessment can contribute to cost-effectiveness (or cost-utility) analysis. In cost-utility 
analysis, quality-adjusted life year (QALY) is often the metric chosen to measure the 
treatment impacts on patient’s health, which combines both measures of the length of life 
and the quality of life.[22] The way to calculate QALY is to multiply the utility value of a 
health state (e.g., health utility measured by EQ-5D) by the years of life lived in that 
heath state.[22] However, this approach may be too generic sometimes to capture the 
impact of treatments on patient’s health in many diseases, and it relies on several strong 
assumptions.[22] Thus, use of QALY for making medical decisions has always been 
controversial and a recent report from European Consortium in Healthcare Outcomes and 
Cost-Benefit Research project even recommended against using QALY for healthcare 
decision-making, since they concluded that QALY is not a scientifically valid 
estimate.[23] It is yet unclear if our approach, combining trial data on specific clinical 
outcomes with patient preferences (trade-offs) for these outcomes, would be better or 
worse as compared to using QALY for making treatment decisions. In the future, 
studying the advantages and disadvantages of our approach versus using QALY in 




 Mover forward, we believe the patient-centered approach to benefit-harm 
assessment developed in this dissertation can be further applied to many diseases and 
settings. A benefit-harm assessment can inform the design, conduct and interpretation of 
a randomized clinical trial. For instance, when clinical trials are designed to compare 
treatments with high toxicity in some disease areas such as cancers, investigators may 
struggle with defining the inclusion/exclusion criteria for trial patients. Concerns that the 
harms may outweigh the benefits in patients with less severe diseases often make it 
difficult to justify the inclusion for such patients. Therefore, using benefit-harm 
assessments to model the benefit-harm balance in treating these patients would help 
investigators deal with the issue.[24] During the conduct of a clinical trial, one major task 
for investigators as well as for Data and Safety Monitoring Committee (DSMC) is to 
monitor treatment efficacy and its safety. In instances where treatments may cause 
various outcomes that occur with different frequency and have different level of severity, 
a quantitative benefit-harm assessment will be helpful to synthesize data and provides a 
guidance for investigators and the DSMC as to whether the trial should be continued or 
should be terminated early for benefits (or for harms).[25] Finally, to interpret the finding 
from a clinical trial, benefit-harm assessment would be valuable as shown by the studies 
conducted in this dissertation. Benefit-harm assessment also plays a role in translating 
evidence generated by clinical trials into clinical practice. It is closely related to the 
development of risk-stratified treatment recommendations by guideline developers since 




 To conclude, in this dissertation we have demonstrated a framework for doing 
patient-centered benefit-harm assessment, which involves selecting patient-centered 
outcomes, eliciting patient preferences, and integrating patients’ perspective into clinical 
trial data on benefits and harms. The applications of our approach will help patients make 
evidence- and preference-based treatment decisions. Our goal is to make medicine more 
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